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ABSTRACT  
   
Understanding intratumor heterogeneity and their driver genes is critical to 
designing personalized treatments and improving clinical outcomes of cancers. Such 
investigations require accurate delineation of the subclonal composition of a tumor, which 
to date can only be reliably inferred from deep-sequencing data (>300x depth). The 
resulting algorithm from the work presented here, incorporates an adaptive error model 
into statistical decomposition of mixed populations, which corrects the mean-variance 
dependency of sequencing data at the subclonal level and enables accurate subclonal 
discovery in tumors sequenced at standard depths (30-50x). Tested on extensive computer 
simulations and real-world data, this new method, named model-based adaptive grouping 
of subclones (MAGOS), consistently outperforms existing methods on minimum 
sequencing depth, decomposition accuracy and computation efficiency. MAGOS supports 
subclone analysis using single nucleotide variants and copy number variants from one or 
more samples of an individual tumor. GUST algorithm, on the other hand is a novel method 
in detecting the cancer type specific driver genes. Combination of MAGOS and GUST 
results can provide insights into cancer progression. Applications of MAGOS and GUST 
to whole-exome sequencing data of 33 different cancer types’ samples discovered a 
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CHAPTER 1 
INTRODUCTION 
Cancer is a major public health problem worldwide and after heart disease is the 
second most common cause of death in the United States. In 2019, it is projected that 
1,762,450 new cancer cases and 606,880 cancer deaths will happen in the United 
States.(Siegel, Miller, and Jemal 2019) 
In spite of the extraordinary amount of effort and money spent on cancer research 
and treatment, it remains difficult to achieve a cure in most cases. Nevertheless, all that 
research has been contributing to the greater understanding of cancer biology, how cancer 
evolves and its complexities. Unraveling the secrets of how cancer evolves and 
progresses is crucial to designing treatment approaches. Like most problems, to find a 
solution, it is vital to understand all aspects of the problem. In cancer, also, in order to 
decide on a treatment approach, it is essential to understand the nature of the disease, how 
it progresses, how it evolves, and how it will react to environmental stresses.   
1.1 Clonal Evolution 
The clonal evolution model proposed by Peter Nowell (Nowell 1976), established 
an evolution model for cancer that a was a foundation for further studies in understanding 
cancer (Greaves and Maley 2012). Nowell suggested that cancer is an evolutionary 
process that is driven by cells acquiring somatic mutations. The accumulation of these 
mutations in a cell affects the fitness of the cell. These mutations, depending on which 
gene they occur in, can give the cell a selective advantage so that the cell proliferates 
faster or survives better than its peers. When this proliferation gets out of control, it can 
result in the death of the host.  Not all of these mutations observed in cancers give the cell 
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a selective advantage. Some may increase the mutation rate in the cell (Sottoriva and 
Graham 2015), and some may be passenger mutations and have no effect on the fitness of 
the cell (Sottoriva and Graham 2015). 
When a cell is hit with a mutation, all its descendants will carry that mutation. As 
mentioned, only some mutations will give the cell a selective advantage, and most 
mutations are passenger mutations, meaning they do not affect the reproduction or 
survival of the cell. The mutations that give the cell a growth or survival advantage are 
called driver mutations (Stratton, Campbell, and Futreal 2009; Christopher Greenman et 
al. 2007).  These mutations happen in cancer genes. The majority of mutations in these 
cells are passenger mutations in comparison to the number of driver mutations that 
provide the cell with selective advantage (Christopher Greenman et al. 2007). The 
mutations in cancer cells can be caused by an error in the DNA repair process or from 
mutagenic exposures, such as ultraviolet light, cigarette carcinogens, and from DNA 
damaging therapies such as chemotherapy (Stratton 2011). Although, mutations can also 
occur just from the normal error rate of DNA polymerases when cells copy their genomes 
during the cell cycle. There are many cancer cases in which causes of the mutations have 
remained unexplained (Stephens et al. 2005). 
Cancers also evolve through clonal expansions. This means that when a driver 
mutation hits a cell, the cell proliferates faster than its peers. All the descendants of that 
mutant cell, called a clone, will share the same genomic profile; hence, they will also 
carry the same mutation. In addition, new cells in that clone may accumulate their own 
new mutations that they maybe passenger or driver mutations. Since the majority of 
mutations are passengers, it is likely that the cells will accumulate more passenger 
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mutations. After some cell generations, the resulting group of cells will share a similar 
genomic profile with passenger and driver mutations. This group of cells, which were 
driven from the initial driver mutation, form a clone that is genetically and may be 
functionally different from the other cells in the neoplasm. In a similar fashion, other 
driver mutations hitting different cells can create different subclones from their 
background genomic profile (Nowell 1976; Greaves and Maley 2012). This will cause 
intratumor heterogeneity, which is discussed in more detail in a later section. It is 
important to note that the term "clone," as mentioned in Nowell (Nowell 1976), implies a 
population of cells descendant from a single cell of origin.   
1.2 Intratumor Heterogeneity 
Cancer development is an evolutionary process that typically originates from a 
single cell or clone and grows into a diverse population of cells via incessant somatic 
mutations and natural selection (Nowell 1976; Greaves and Maley 2012). In this dynamic 
process, different cell populations (i.e., subclones) emerge, expand and diminish over 
time and space, leading to a heterogeneous malignancy with multifarious clinical 
presentations. This dynamic often results in two types of heterogeneity; intertumor 
heterogeneity and intratumor heterogeneity (J. Liu, Dang, and Wang 2018).  
Intertumor heterogeneity refers to the differences between tumors, even if they are 
the same clinical type. There are differences in the genomic profiles of the tumor samples 
from different patients. Intertumor heterogeneity in part is because of the altered 
genotype and phenotype of the patients from etiological and environmental factors 
(Davidson et al. 2016; Llovet, Burroughs, and Bruix 2003), and also the fact that 
acquiring mutations in cells is not deterministic and mutations may hit different genes in 
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different patients. Intratumor heterogeneity, on the other hand, refers to the within tumor 
heterogeneity, meaning the tumor is composed of various populations of cells with 
different genomic alterations, which is the result of the mutations and clonal expansion 
within a cancer. The driver mutations generate these subpopulations, and the passenger 
mutations are carried in the clonal expansions. 
Understanding intratumor heterogeneity is critical to understanding the dynamics 
of the disease. Most cancer therapies eliminate some clonal populations but not all 
(Aktipis et al. 2011). Better understanding the composition of the tumor will have 
significant clinical implications in designing treatments. Understanding this dynamic 
system provides valuable knowledge to facilitate early diagnosis, effective treatment, and 
outcome monitoring of cancers (Aktipis et al. 2011; Andor et al. 2014; Nik-Zainal et al. 
2012; Gerlinger and Swanton 2010; Fisher, Pusztai, and Swanton 2013; Ma, Ennis, and 
Aparicio 2012). Before explaining the therapeutic effects and importance of this clonal 
structure and intratumor heterogeneity, it is essential to talk about the different types of 
mutations, the genes they hit, and their effects on cancer progression. In the next section, 
we explain different types of mutation, what sort of hallmarks are essential to the 
development of cancer and the role of mutations in the cell acquiring these hallmarks. 
1.3 Cancer Hallmarks and Driver Mutations 
Gene alterations in the body are called germline mutations if they are in the sperm 
or egg that fused to generate the first cell of the body (the zygote) and are inherited in the 
DNA of every cell in the body. Germline mutations are passed on from parents to their 
children, and they exist in all of the cells, whereas the somatic mutations are alterations 
that can happen in the non-germ cells (the somatic cells) during the lifetime of an 
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organism. They are only passed to the decedent of that specific cell and not the other cells 
in the body. Tumorigenesis, which means the process of formation of a tumor, is believed 
to be a consequence of somatic mutation accumulation, including base substitutions, 
insertions and deletions of bases, inversions, translocations, and changes in the copy 
number of DNA segments, in the genome of cancer cells (Christopher Greenman et al. 
2007; Tao et al. 2011; Harrington 2016). Germline mutations can predispose a person to 
heritable cancer, either by providing one of the sufficient mutations to cause a cancer, and 
thereby  reducing the number of mutations that must be accumulated to complete the 
process of tumorigenesis, or by increasing the mutation rate in somatic cells (Croce 2008; 
Stratton 2011). 
As previously discussed, mutations can be divided into passenger and driver 
mutations (Segal et al. 2008). Driver mutations are the ones that confer a fitness 
advantage in some way and contribute directly to tumorigenesis. The contribution to 
tumorigenesis can also be explained in the concept of hallmarks of cancer (Fortunato et 
al. 2017).  
Cancer hallmarks are biological capabilities that cancer cells acquire during 
tumorigenesis. These capabilities are vital in the progression of cancer, and with all of 
them at work, cancer cells can survive, and tumors can grow. There are eight important 
hallmarks proposed by Hanahan et al., including sustaining proliferative signaling, 
evading growth suppressors, ignoring apoptosis signals, enabling replicative immortality, 
inducing angiogenesis, altering cell metabolism, evading the immune system, and 
activation of metastasis and invasion (Hanahan and Weinberg 2011). These 
complementary traits enable tumorigenesis. Understanding how these capabilities are 
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activated is key to understanding the cancer progression. These hallmarks are activated 
and induced by somatic alterations in different genes. Some of the hallmarks are the 
result of a gene being activated and gain function, and some are the result of a gene 
losing its function and being deactivated. The genes that are activated by acquiring 
mutations are called proto-oncogenes, and the genes that lose their functions are called 
tumor suppressor genes. Once a proto-oncogene acquires a mutation that increases the 
chance of cancer, the mutated gene is called an oncogene. However, the distinction 
between proto-oncogenes and oncogenes is somewhat esoteric, and in practice is often 
ignored. Here, for simplicity, I will just refer to them as oncogenes. Oncogenes are genes 
that are cancer causing when activated, typically causing increased proliferation of the 
clone. Their activation causes the oncogenesis, which is the process in which a healthy 
cell transforms into a cancer cell, which leads to the cell to proliferate in an uncontrolled 
manner (Krump and You 2018). The tumor suppressor genes, on the other hand, are 
genes that increase the chance of developing cancer when they are deactivated. These 
genes are responsible for sensing and responding to DNA damage, repairing DNA, 
sending apoptosis signals or preventing the cell from proliferating uncontrollably (Morris 
and Chan 2015).  
Since the driver genes are the main reason for oncogenesis, being able to identify 
these genes can reveal the mechanism of the disease progression. It becomes very 
important to be able to identify driver mutations and driver genes. These identifications 
need to be supported by independent observation of these events occurring more frequently in 
multiple neoplasms than the expected in the normal sample (Greaves and Maley 2012; Maley et 
al. 2004; Llovet, Burroughs, and Bruix 2003). The type of mutation (silent, missense or nonsense) 
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is also important in classifying it as driver or passenger (Bignell et al. 2010; Youn and Simon 
2011). In the next section, we discuss the clinical implications of the tumor heterogeneity, the 
current approaches and their shortcomings.  
1.4 Therapeutic Importance and Current Approaches to Study Tumor 
Heterogeneity 
Understanding the dynamic system behind the progression of cancer provides 
valuable knowledge to facilitate early diagnosis, effective treatment, and outcome 
monitoring of cancers (Aktipis et al. 2011; Andor et al. 2014; Nik-Zainal et al. 2012; 
Gerlinger and Swanton 2010; Fisher, Pusztai, and Swanton 2013; Ma, Ennis, and 
Aparicio 2012). The heterogeneity in the tumors results in a non-uniform and genetically 
diverse population of cells both across the tumor at a single time point (spatial 
heterogeneity) or across different time points (temporal heterogeneity).  
The heterogeneity in the tumor is the main cause of resistance to therapy in 
cancers; therefore, controlling the disease and designing the best therapy approach 
depends on understanding this subclonal structure (Dagogo-Jack and Shaw 2018; Hiley et 
al. 2014). 
Because mutations in driver genes cause cancer, an important approach to therapy 
has been the development of drugs that target those driver genes (Higgins and Baselga 
2011; Morris and Chan 2015; Sawyers 2004). This is one reason that identifying the 
oncogenes and tumor suppressor genes is important. Detecting the driver genes can also 
help with early detection of the disease, identifying risk factors, and generating animal 
models of cancer. Ideally, we would like to therapeutically reactivate tumor suppressor 
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genes and deactivate oncogenes, though at present we only have methods to deactivate 
oncogenes, and even in that case, we only have been successful at inhibiting oncogenes 
that are tyrosine kinases.  
The clonal structure of a tumor can provide valuable information. It is essential to 
identify the driver genes and then study whether they are clonal mutations or subclonal 
mutations. Because in most cancers, it is the clonal mutations that are driving the 
progression of cancer, but it is the rare mutations that are subclonal that cause relapse and 
often resistance to different therapies (Hinohara and Polyak 2019; Schmitt, Loeb, and 
Salk 2016). 
Whole-exome or whole-genome sequencing is a common approach to studying 
intratumor heterogeneity (Schwartz and Schäffer 2017; Egan et al. 2012; Landau et al. 
2013). By tracking relative abundances of genomic variants in a collection of cancerous 
cells, scientists aim to quantify the genetic diversity of a tumor and to reconstruct the 
phylogeny of subclones. The underlying principle is that cells of similar genetic 
compositions belong to the same clone. While single-cell sequencing is on the rise, bulk 
sequencing remains the dominant technology used to interrogate an amalgam of 
heterogeneous cells collectively. Researchers rely on in silico analysis to de-convolute 
the mixed populations of clones within the sample.  Single-cell sequencing is a promising 
technology to examine the genetic compositions of individual cells, but it currently  
suffers from low and uneven genome coverage, low accuracy of variant calls, and 
prohibitive cost which all limit its usage for subclonal investigations (Gawad, Koh, and 
Quake 2016). The majority of current studies perform bulk sequencing of tens of 
thousands of heterogeneous cells from a tumor followed by clonal deconvolution. In 
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some studies, generic clustering tools (Fraley and Raftery 1999) and packages have been 
used to analyze the bulk sequencing data (Ding et al. 2012), but the problem with this 
approach is that some manual curation is required. In addition, these methods are not 
tuned to use sequencing information such as sequencing depth and Variant allele 
frequency (VAF). Several methods have been developed to address this weakness, such 
as SciClone (C. A. Miller et al. 2014), PyClone (Roth et al. 2014), and Expands (Andor et 
al. 2014). Despite algorithmic differences, these methods make a common assumption 
that variant allele frequency (VAFs, i.e., the fraction of reads containing the mutant allele 
among total reads) is indicative of the relative abundance of cells carrying these 
mutations. Thus, subpopulation discovery is translated into grouping mutations with 
similar VAFs in a tumor. If multiple samples of a tumor are sequenced, mutations 
defining a subpopulation are expected to have concordant changes of VAFs across these 
samples. The discovered subclones can be further analyzed to infer phylogenetic 
relationships, test for selection, and other analysis regarding tumor heterogeneity and 
clonal evolution of the disease. SciClone and PyClone are able to analyze multiple 
samples but EXPANDS can only do single sample analysis.  
1.5 Limitations of Existing Methods 
Next-gen sequencing technologies have opened a vast range of genomic analysis 
capabilities to researchers (Shendure and Ji 2008; Meldrum, Doyle, and Tothill 2011). 
Whole-genome and whole-exome sequencing are becoming the standard approach to 
study the clonal evolution in cancer as well. These sequencing technologies produce the 
counts of reference and alternate reads on each sequenced position. The total number of 
sequenced DNA segments that cover a position is referred to as the coverage or 
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sequencing depth.  The variant allele frequency (VAF) is defined as the number of 
alternate reads divided by the sequencing depth, which is the sum of the reference reads 
and the alternate reads. The VAF is the feature used in the existing algorithms for 
detecting the clonal structure in tumors. Because of the reliance on VAFs, existing 
methods require the sequencing depth of a tumor sample to be at least 100x coverage, or 
suggest a minimum number of mutations (Miller et al. 2014; Andor et al. 2014). Some of 
them were even developed to work on only deeply sequenced data (depth>1000x) (Roth 
et al. 2014). They are not suited for samples sequenced at a standard 30-50x depth (Sims 
et al. 2014). This precludes their use on the overwhelming majority of samples sequenced 
to date, including those generated by collaborative consortia, such as the TCGA Pan-
Cancer Atlas (average depth = 68x). Unfortunately, clinical samples are often sequenced 
at a much lower depth, since 30x-50x is considered sufficient to call germline mutations 
with high confidence (Griffith et al. 2015). 
An independent evaluation of SciClone showed that consistent clonal 
identifications can only be produced when the sequencing coverage is 300x or higher 
(Griffith et al. 2015). Given the constraint on the sequencing depth of existing methods, 
valuable information embedded in tens of thousands of tumor genomes is unexploited. 
New methods to characterize subclonal structure accurately from sequencing data at a 
shallow-to-medium coverage are urgently needed.  
At the algorithmic level, the constraints of sequencing depths in current methods 
are at least partially due to unexplained variances in bulk sequencing data. A key 
assumption taken by these methods is the correspondence between variant allele 
frequencies (VAFs, i.e., the fraction of reads containing a specific mutant allele among 
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total reads) and cellular prevalence (i.e., the fraction of cells carrying this particular 
mutant among all cells). Subclone discovery is then translated into a task of clustering 
similar VAFs (Miller et al. 2014). However, VAFs are also influenced by technical 
factors, such as sequencing depth. Due to randomness in sequencing procedures, the 
same subclone may give rise to a dispersed cluster of VAFs when sequenced at a low 
depth, but a tight cluster of VAFs when sequenced at a high depth (Griffith et al. 2015). 
The spread of VAFs also correlates with cellular prevalence. VAFs of variants in a 
common subclone are expected to scatter more broadly than those in a rare subclone 
(Griffith et al. 2015). Without considering these confounders, subclones reported by 
current methods are inevitably adulterated, especially when the sequencing depth is not 
high enough to create strong contrasts between subclones with similar cellular 
prevalence. 
To detangle these technical variabilities from biological variabilities, we have 
developed a new method, named model-based adaptive grouping of subclones (MAGOS) 
that explicitly models the impact of sequencing depth and cellular prevalence on the 
variance of VAFs in subclone decomposition. Cellular prevalence refers to the proportion 
of cancer cells in the sample that share the same group of mutations. Through extensive 
tests using computer simulations and real-world data, we show that MAGOS can 
accurately delineate subclonal structures of tumor samples sequenced at depths as low as 
30x. MAGOS is also the fastest program when compared to SciClone and PyClone, 
showing an acceleration of 3-20 fold. We implemented MAGOS as an R package that is 
freely available at GitHub (https://github.com/liliulab/magos).  
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In the next chapter, we discuss the approach we took and explain the principles 
and the methods that MAGOS uses in contrast to the commonly known algorithms, then 
we present the results of the simulations we ran for the evaluation of MAGOS and the 
results of executing MAGOS on the 33 cancer projects publicly available on TCGA. In 
the third chapter, we introduce GUST, which is an algorithm that identifies cancer 
specific driver genes. We evaluate its performance and present the results of executing 
GUST on the TCGA data. In the fourth chapter, combine the results of MAGOS with 
GUST to find the (sub)clonal distribution of driver genes and report if there are any 
features with prognosis value. 
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CHAPTER 2 
MODEL-BASED ADAPTIVE GROUPING OF SUBCLONES: MAGOS 
The purpose of MAGOS, as well as the other existing algorithms, is to group 
variants that emerge and evolve together into a cluster based on similarities of VAFs. 
Each cluster thus corresponds to a subclonal expansion. In this context, we use the VAF 
cluster and subclone interchangeably.  
Each method has a different approach to finding the mutational clones. Some of 
them were designed to work on a specific type of data, but they have been used in various 
studies before. PyClone, SciClone, and EXPANDS are the algorithms that are used in the 
most recent studies. Each has its limitations and assumptions. In here, we will discuss 
their approached and limitations. 
2.1 Existing Methods and Their Limitations 
2.1.1 PyClone 
PyClone is a Bayesian clustering method for grouping sets of deeply sequenced 
mutations into clonal and subclonal clusters. PyClone requires the mutations to be deeply 
sequenced at coverage > 1000x. It can also be used to cluster sequenced mutations across 
multiple samples. The primary assumption in the PyClone approach is that no site can be 
mutated more than once, and the mutations do not disappear (they do not revert to 
wildtype). The allelic prevalence of mutations has information from several sources in it. 
It contains normal contamination, meaning the proportion of contaminating normal cells 
in the sample (purity), the proportion of cells carrying the mutation, and technical noise. 
The main advantage of the analysis of multiple sequencing samples (temporal or spatial) 
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is the possibility of sets of mutations that their VAFs shift together. This is a great way to 
identify and separate the clones and mutations that are proliferating in different rates.  
PyClone is a hierarchical Bayesian statistical model. The inputs of the model are a 
set of deeply sequenced mutations from one or more samples from the same cancer. 
PyClone output is the posterior densities for the model parameters and the clonal 
structure of the mutations. PyClone uses Beta-Binomial densities over Binomial models 
because it has more efficiency in modeling the datasets with more variance in allelic 
prevalence measurements. It also utilizes Bayesian non-parametric clustering to discover 
groupings of mutations and the number of groups concurrently. This eliminates the need 
for fixing the number of clusters a priori and allows cellular prevalence estimates to 
reflect uncertainty in this parameter.  
The PyClone package provides tools for performing Dirichlet Process clustering 
of mutations. The model outputs a posterior density for each mutation’s VAF and a 
matrix containing the probability that any two mutations occur in the same cluster. Then 
the model merges two mutations to the same cluster if they have similar VAF in the 
sample(s). To obtain a flat clustering of the mutations from the matrix of pairwise 
probabilities, we construct a dendrogram and find the cut point that optimizes the 
MPEAR criterion (Fritsch and Ickstadt 2009). More detailed information on the PyClone 
method is available in Roth et al (Roth et al. 2014). 
The traditional view of clonal heterogeneity and tumor phylogenies is to cluster 
cells by their mutational composition — however, PyClone clusters mutations that appear 
at similar cellular frequencies (similar VAFs). In simple cases, where there is only one 
clone, the clustering derived may be correct; however, if multiple subclones exist at 
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similar cellular frequencies, the model will cluster the associated mutations together and 
fails to identify distinct clusters. The mutations get separated, and we start to see a 
contrast between the VAFs of mutations from different clusters as we increase the 
sequencing depth. Sequencing multiple samples also helps to identify the correct clusters 
in these situations because it is expected that the mutations from the same cluster shift 
together and have similar VAF across all samples.  
PyClone is specifically designed for the problem of inferring the clonal structure 
of single nucleotide mutations in deeply sequenced tumor samples. However, the model 
is quite generic in the sense that it only assumes the sequenced sample is a heterogeneous 
mixture of cells. Because of this fact, PyClone is not recommended to be used on low 
coverage data. The results from PyClone on low coverage input are not consistent. 
Another limitation of PyClone, specifically on single samples with low coverage 
sequencing, is the fact that it tends to over-estimate the number of clusters; it finds 
additional clusters with only a single or a few mutations assigned to them. Because of 
these limitations, using PyClone on samples similar to TCGA data is not recommended.  
2.1.2 SciClone 
SciClone is a method for identifying the subclones across one or many samples 
and estimate the number of existing subclones. It mainly focuses on the copy-number 
neutral(diploid) and loss of heterozygosity free regions of the genome, which leads to 
higher confidence variant allele frequencies and inference on the clonality. However, it 
limits the number of mutations that can be analyzed since many cancers are highly 
aneuploid. The regions of copy number alterations and the loss of heterozygosity are 
provided as an input from whole-genome sequencing or whole-exome sequencing. The 
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single nucleotide variants should be sequenced at a sufficient depth from whole-exome 
sequencing or deeply sequenced from targeted sequencing. The approach that SciClone 
takes can be used on any input that can be described as a frequency.  
In SciClone, the clustering of the VAFs is performed using a variational Bayesian 
mixture model (VBMM) (Bishop 2006). Several approaches, before SciClone, have taken 
Dirichlet process models to perform clustering(Roth et al. 2014; Shah et al. 2012) since 
they could automatically infer the number of clusters. VBMMs, in addition to 
automatically inferring the number of clusters and providing probabilistic interpretations 
of the clusters, can be scaled to high dimensions and have an efficiency advantage over 
MCMC techniques that are used in the algorithms before SciClone.  
One fundamental principle in identifying the subclones is mixture modeling. The 
mutations from different subclones are mixed in the bulk sequencing data, and the 
observed data is a representation of that mixture. SciClone’s fundamental objective is to 
identify the subclones from the mixture. The VAF is defined as the number of alternate 
reads over the total number of reads. The distribution of the VAF from each cluster is 
assumed to have a beta distribution. The probability of each mutation coming from each 
cluster is then determined by using the probability distribution function of each cluster. 
The SciClone model is initialized by performing k-means clustering on the data 
with ten initial clusters. This adds randomness to the clustering, and local optima may be 
selected. This may lead to inconsistent results in some samples. SciClone also removes 
any clusters having less than the largest of three variants or 0.5% of "N," the total number 
of mutations. So it is biased against finding clones with few mutations. If clusters are 
removed, the algorithm is again executed until it reaches convergence.  
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Based on the analysis on Miller et al.(Miller et al. 2014), SciClone can be useful 
on samples with as few as 29 SNVs, and in more complex cases,  identifying the 
subclones may require two hundred or more variants and that subclones be separated by 
VAFs of ∼7% or more. 
The accuracy of the detected subclones is increased with the number of mutations 
in the data. In exome-sequencing, many passenger mutations are likely to be missed; 
thus, whole-genome sequencing is more likely to capture the full spectrum of mutations 
and produce a high confidence clonal structure. Also, SciClone is also able to incorporate 
additional temporal or spatial samples into its analysis to provide a more accurate view of 
the subclonal structure of the tumor. The suggested minimum coverage of SciClone is 
100x, which limits the use of this approach on low coverage data. This is shown in the 
results chapter. 
2.1.3 EXPANDS 
EXPANDS is another algorithm designed to identify these subpopulations in a 
tumor using allele frequencies (VAFs) from whole-exome or whole-genome sequencing 
and copy number alterations. EXPANDS estimates the tumor purity as well. 
The EXPANDS model (Andor et al. 2014), similar to previous approaches, makes a few 
assumptions. First, it assumes that each locus is mutated only once. Meaning cells are 
mutated in that locus, or they are normal. It means the mutation occurs at a single time 
point, and all the cells carry that mutation are descendants of the original cell. The same 
mutation is not likely to occur in multiple distinct cells independently. Another 
assumption is that multiple passenger mutations accumulate in a cell before a driver 
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mutation hits the cell and causes clonal expansion. SciClone and PyClone also have this 
assumption.  
The EXPANDS model uses these assumptions in four steps. Cell frequency 
estimation, clustering, filtering, and assignment of mutations to clusters. In the first step, 
using the single nucleotide variations and the copy number information, EXPAND 
combines both information inputs and estimates the fraction of cells carrying each 
mutation. Thus, it does not require mutations to be in diploid regions of the genome. If all 
mutations are from diploid regions, then the measure directly translates into VAF. If the 
mutation occurs in an aneuploid region of the genome, the VAF must be scaled by the 
number of copies in which it occurs before the clone’s frequency can be estimated. Since 
the equations used at this step are not deterministic, the results for the cell frequency 
estimation are in a probability form as a function of f in the range [0,1] (p(f)= probability 
that the mutation has VAF=f). In the clustering step, mutations are clustered based on 
their cell frequency probability distributions. The clustering is performed in two steps. 
The aim of the clustering step in EXPANDS is to merge mutations that have common 
peaks in their p(f) distribution. The mutations are grouped together by hierarchical 
clustering of the p(f)s using Kullback-Leibler divergence as a distance measure (Joyce 
2011). Then, the cell frequency at each cluster maxima is considered as the size of the 
cluster. In the second step, each cluster is extended by mutations with similar 
distributions in an interval around the cluster maxima.  
In the filtering step, the clusters that all the mutations assigned to them all have the same 
cell frequency as each other. EXPANDS calculates the tumor purity is the size of the 
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largest subclone. Then each locus is assigned to the cluster that its cell frequency 
estimation is closest to.  
EXPANDS is sensitive to the mutation count as well as the coverage of the 
mutations. The prediction accuracy of EXPANDS increases with the number of 
mutations. EXPANDS also tends to over-estimate the number of clusters and in lower 
coverage data fails to detect the correct number of clusters. This makes EXPANDS a 
poor candidate for analyzing samples with a small number of mutations and low 
coverage.  
2.2 MAGOS Algorithm 
We designed MAGOS in a way so that it has better performance on low coverage 
data, as well as high coverage. In the rest of this chapter, we discuss how MAGOS works. 
In the Results chapter, we discuss evaluations and comparisons we ran on real and 
simulated data. 
MAGOS discovers subclones from bulk sequencing data based on the concept of 
mixture distributions. It represents VAFs of somatic mutations that occur and evolve 
together as samples drawn from a beta distribution. When multiple subclones are present, 
the observed VAFs are a mixture of samples from multiple beta distributions. Therefore, 
the identification of subclones is equivalent to decomposing mixed beta distributions.  
MAGOS supports subclone analysis of a tumor containing single nucleotide variants 
(SNVs) and copy number variants (CNVs) obtained from one or more samples. To 
illustrate the algorithms of MAGOS, we start with simple scenarios and gradually 
introduce complexities into the data model. 
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2.2.1 Algorithm for SNVs from Single Sample 
The simplest scenario involves a single tumor sample that has only SNVs, no 
CNVs and no contamination of normal cells. The goal is to group the mutations that 
belong to the same (sub)clone and estimates its frequency. For this, we need to find 
clusters of SNVs with similar VAFs. Given a variant 𝑖, we denote the total number of 
reads aligned to this position as its sequencing depth 𝑒𝑖, and denote the fraction of reads 
containing the mutant allele among all reads as its VAF 𝑣𝑖 ∈ (0, 1).  For a set of 𝑚 
variants belonging to the same subclone, we model their VAFs as random samples from a 
beta distribution 𝐵𝑒𝑡𝑎(𝛼, 𝛽) and require the two shape parameters (𝛼 and 𝛽) to satisfy  
{
𝛼 + 𝛽 = ?̅?
𝛼
𝛼+𝛽
= ?̅?          (1) 
where ?̅? is the mean sequencing depth and ?̅? is the mean VAF of these variants. This 
configuration has the desired property that the variance of the beta distribution is 
positively correlated to the mean VAF and negatively correlated to the mean sequencing 
depth. The proof of this concept is in Appendix A. Through this setup, we link the 
variance of VAFs to cellular prevalence and sequencing depth. 
When multiple subclones are present, the observed VAFs are a mixture of 
samples from multiple beta distributions, each defined by a set of shape parameters. 
Therefore, identification of subclones is equivalent to decomposing mixed beta 
distributions (Fig. 2.1). We solve this problem with a two-phase algorithm that performs 
agglomerative hierarchical clustering and adaptive partitioning.  
 








Figure 2.1. Beta mixture distribution.  The observed distribution (black curve) of VAFs is 
a combination of multiple hidden groups of VAFs, each forming a beta distribution 
(shaded curves) defined by different parameters.   
 
In the first phase, we organize variants into a hierarchical tree structure by 
progressively grouping variants with similar VAFs into a cluster. Starting with leaf nodes 
each consisting of an individual variant, we iteratively merge a pair of nodes with the 
shortest distance (defined below) among all pairs to create a new cluster till all variants 
are merged into one root cluster (Fig. 2).  Given two nodes (i.e., clusters), 𝐶1 𝑎𝑛𝑑 𝐶2 
consisting of 𝑚1 and 𝑚2 variants, respectively, we define their distance 𝑑 as a weighted 
sum of negative log likelihood that VAFs of all variants in 𝐶1 𝑎𝑛𝑑 𝐶2 are drawn from the 
same beta distribution,  
𝑑(𝐶1,  𝐶2) = 𝑤 ∑ −log (P(𝑣𝑖 ;  𝐵𝑒𝑡𝑎(𝛼, 𝛽)))𝑖∈{𝐶1, 𝐶2}    (2) 
where 𝛼 and 𝛽 are calculated by solving equation (1) and the weight 
𝑤 = 1 (𝑚1 + 𝑚2) ∙ 𝑣𝑎𝑟(𝑣) ∙ 𝑟𝑎𝑛𝑔𝑒(𝑣)⁄ . Because the distance is down-weighted by the 
variance and range of VAFs, given two pairs of clusters with similar values of log 
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likelihood, MAGOS will choose the pair with a smaller variance and a narrower range to 








Figure 2.2. We start with 5 clusters each containing a single mutation, i.e., {1}, {2}, {3}, 
{4}, {5}. We then fit a beta distribution on each possible pairwise combinations of the 5 
mutations, which produces 10 corresponding d values. Because the pair {2} and {3} has 
the minimum distance, we put them together to create a new cluster {2, 3}. Next, we 
compute the pairwise distance between the remaining 4 clusters and merge {1} and {2, 
3} because their distance is the smallest. We iterate this process until all mutations are 
merged into a single cluster, i.e., the root. 
 
In the second phase, we identify boundaries of distinct beta distributions by 
traversing and partitioning the tree into clades (i.e., aggregation of clusters below a 
branching point). Unlike traditional approaches that cut the tree at a fixed branch level, 
we perform an adaptive splitting (Fig. 2.3). Along the root-to-leaves path, we examine 
the clade at each branching point and test the null hypothesis that VAFs in this clade are 
drawn from the same beta distribution. This is done by comparing the observed variance 
of VAFs with the expected variance of VAFs. Specifically, given a clade containing 𝑚 
variants, we assume they belong to the same subclone and compute 𝛼 and 𝛽 by solving 
equation (1). We then draw 𝑚 random samples 𝑥1:𝑚~𝐵𝑒𝑡𝑎(𝛼, 𝛽) and calculate 𝑣𝑎𝑟(𝑥). By 
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repeating this process 1,000 times, we derive 1,000 𝑣𝑎𝑟(𝑥) values representing the null 
distribution. We then use one-sample one-sided t-test to evaluate if 𝑣𝑎𝑟(𝑣)  ≤ 𝑣𝑎𝑟(𝑥). We 
reject the null hypothesis if the p-value < 0.01, which indicates VAFs of this clade are 
from heterogeneous beta distributions and need to be partitioned further. Otherwise, we 
consider this clade as homogeneous and stop traversing below this branching point. We 
repeat this process till we find homogeneous clades along all branches or we reach the 









Figure 2.3. Hierarchical clustering and adaptive partitioning. In this example, ten variants 
at the leaf nodes are progressively grouped into clusters based on VAF similarities to 
form a tree structure. To partition the tree, we follow the root-to-leave paths. At each 
branching point, the variance of the VAFs of the clade is compared with the expected 
variance. A cluster is accepted if the variance is lower than the expected value. 
Otherwise, it is rejected and partitioning continues (marked by black crosses). In this 
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2.2.1.1 Algorithm for CNVs in Single Sample 
For variants located in CNV regions, we assume they do not form new clusters 
but instead belong to clusters identified from the diploid SNV analysis. Given a variant 𝑖, 
the expected VAF 𝑣𝑖
′ reflects the cellular prevalence 𝜌, average ploidy 𝜑 of the genomic 





      (3) 
Note that 𝜑 is the average ploidy of the focus region in the entire sample and 
takes a continuous value. Finding the cluster assignment 𝑔 from among existing SNV 









|    (4) 
where 𝑣𝑖 is the observed VAF. We limit the search space of 𝑘 to integers between 1 and 
10 × 𝜑.  
2.2.2 Algorithm for SNVs from Multiple Samples 
When multiple samples of a tumor are analyzed, we expect that VAFs 
representing the same subclone to change concordantly across all samples. However, 
because the sequencing depth and cellular prevalence of a subclone vary across samples, 
we need to estimate the beta distribution of this subclone in each sample separately.   
MAGOS takes two matrices (𝑅 and 𝐶) as inputs. The matrix 𝑅 contains the 
number of reads mapped to the reference allele (𝑒𝑟,𝑖
𝑠 ) and the number of reads mapped to 
the alternative allele (𝑒𝑎,𝑖
𝑠 ) for each SNV 𝑖 in each sample 𝑠. The matrix 𝐶 contains the 
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average ploidy (𝜑𝑗
𝑠) of each CNV 𝑗 in each sample 𝑠. We categorize SNVs into two 
groups based on if they are located in regions affected by CNVs.  




𝑠  and VAF is 𝑣𝑖
𝑠 = 𝑒𝑎,𝑖
𝑠 /𝑒𝑖
𝑠. Given a collection of such SNVs, our task is to 
organize them into groups so that SNVs in the same group have similar VAFs that are 
significantly different from variants in a different group. We achieve this task with a two-
phase hierarchical clustering and adaptive partitioning algorithm. 
In the hierarchical clustering phase, we start with leaf nodes each consisting of an 
individual SNV, and iteratively merge a pair of nodes with the minimum distance among 
all pairs to create a new cluster till all SNVs are merged into one root cluster. We define 
the distance between two nodes (i.e., clusters) 𝐶1 and 𝐶2 as 






𝑠 ;  𝐵𝑒𝑡𝑎(𝛼𝑠, 𝛽𝑠)))𝑖∈{𝐶1, 𝐶2}   (5) 
where 𝑣𝑠 = {𝑣𝑖
𝑠}  for 𝑖 ∈ {𝐶1,  𝐶2}, and 𝛼
𝑠 and 𝛽𝑠 are the two shape parameters of a beta 
distribution computed by solving  
{




     (6) 
where 𝑒𝑠 = {𝑒𝑖
𝑠}  for 𝑖 ∈ {𝐶1,  𝐶2}. 
In the adaptive partitioning phase, we traverse the tree along the root-to-leaf path. 
At each branching point, we examine the clade that includes all SNVs below this point. If 
a clade contains 𝑚 variants that belong to the same subclone, VAFs of these variants in 
each sample must come from the same beta distribution, 𝑣𝑠~𝐵𝑒𝑡𝑎(𝛼𝑠, 𝛽𝑠). To test this 
hypothesis, we first calculate values of 𝛼𝑠 and 𝛽𝑠 by solving equation [9] for each 
sample 𝑠. We then draw 𝑚 random samples 𝑥1:𝑚
𝑠 ~𝐵𝑒𝑡𝑎(𝛼𝑠, 𝛽𝑠) and calculate 𝑣𝑎𝑟(𝑥𝑠) =
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∑(𝑥𝑠 − 𝑥𝑠̅̅ ̅)2 /𝑚. By repeating this sampling process 1,000 times, we derive 1,000 𝑣𝑎𝑟(𝑥𝑠) 
values representing the null distribution. Using the one-sample one-sided t-test, we assess 
if 𝑣𝑎𝑟(𝑣𝑠)  ≤ 𝑣𝑎𝑟(𝑥𝑠). A p-value >0.01 indicates that VAFs of this clade in sample 𝑠 are 
indeed from the same beta distribution (i.e., homogeneous). We perform this test for all 
samples and accept the null hypothesis if all samples produce p-values >0.01.  Then, we 
stop traversing below this branching point and consider variants in this clade constitute a 
subclone. Otherwise, we will partition this node by following the path and examine the 
clades at the next lower level. We repeat this process until we find homogeneous clades 
along all branches or we reach the leaf nodes. Each of the resulted homogeneous clade 
then represents a unique subclone. 
2.2.2.1 Algorithm for CNVs in Multiple Sample 
Next, we match SNVs located in CNV regions to subclones identified from the 
above analysis. Given a SNV 𝑗 located in a CNV region that has an unknown copy 









𝑠 |𝑠      (7) 
where 𝜑𝑗
𝑠 is the average ploidy of the region harboring this variant, and 𝑣𝑔
𝑠̅̅ ̅ is the mean 
VAF of subclone 𝑔 identified from the previous analysis using only SNVs not affected by 
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2.2.3 Optimization to improve computational efficiency 
The standard hierarchical agglomerative clustering procedure requires calculations of 
all pairwise distances at each step, which leads to an exponential increase of computational 
complexity as the number of variants grows. However, given the narrow range of VAFs 
between 0 and 1, not all pairwise comparisons are necessary, especially for variants with 
highly similar VAFs across all samples. Eliminating unnecessary comparisons is 
particularly important at the initial clustering steps because the computational complexity 
of a bifurcating tree is roughly determined by the number of leaf nodes. Based on this 
principle, we have identified several scenarios in which clusters can be formed without 
exhaustive search.  
 For a single tumor sample 
o If the differences of VAFs of some mutations are too small (< 0.01) to be 
meaningful, these mutations are collapsed into one cluster immediately 
above the leaf nodes. 
o By sorting VAFs in an ascending order, it is only necessary to compare 
adjacent VAFs of leaf nodes. 
 For multiple tumor samples 
o Given a set of mutations, if the differences of their VAFs in all samples are 
< 0.01, we collapse them into one cluster. 
o If we are performing clustering on a large number of mutations, we break 
them into smaller groups and analyze them in smaller sets. This approach is 
discussed in the next section. 
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2.2.3.1 Single Sample Optimization 
In single sample clustering, we only have one set of VAFs. If we have 𝑛 
mutations to cluster, there will be (𝑛
2
) possible pairwise combinations. We use an upper 
triangular matrix to store the distances. In this matrix, the element in row 𝑖 and column 𝑗 
corresponds to the distance between mutation  𝑖 and 𝑗. After finding the minimum 
distance, the corresponding row and column are removed from the matrix, but a new 
column and row are added which will store the distances between the new cluster and the 
other unchanged clusters. We update this matrix until the last step that the matrix is 
reduced to a 2 by 2 matrix, which corresponds to the last step of merging where there are 
only two clusters left to be merged. For large a number of mutations, the pairwise 
calculations will slow down the process and many computed distances are never used. 
For example, in the first step, we do not need to calculate distances between mutations 
that are far from each other. In order to make the process more efficient, first, we sort the 
VAFs, and then we calculate the distances between the mutations that are next to each 
other. Because we know that for three mutations, we will merge the closest one first and 
there is no need to calculate the distance between the points with higher distance (Fig.4). 









Figure 2.1: For 5 mutations (5
2
) = 10 need to be calculated then the pair with the lowest 
distance are merged. As for the optimized version (on the right) only 4 calculations are 
needed. As number of mutations increase this difference, contribute largely to 
computation speed. For 𝑛 mutations (𝑛
2
) calculation is needed but for optimized version, 
only 𝑛 − 1.  
Another approach that makes the process faster in single sample clustering is that 
in the preprocessing step, we round the VAFs and collapse the identical ones into one 
cluster. This will significantly reduce the number of irrelevant computations. For a large 
number of mutations, the mutations are rounded to two decimal points. The mutations with 
the exact VAF are merged. The total possible number of starting clusters will reduce to 99 
(clusters with mean VAF of 0.01 to 0.99). The hierarchical clustering is then performed on 
the resulting clusters, and a lot of lengthy initial steps are eliminated. 
 
2.2.3.2 Multiple Sample Optimization 
Although the optimization steps in the single sample approach significantly speed 
up the process, not all of them can be extended to multiple sample clustering because we 
have more than one set of mutations, and sorting VAFs based on one sample will not help 
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much. The computational issue for the multiple sample approach is that we add another 
dimension to our computations. This means that for every pair of mutations, we need to 
compute the distance between the two across all samples.  The pairwise comparison is the 
nature of the hierarchical clustering. In single sample optimization, we managed to avoid 
doing all the pairwise calculations because we could sort the mutations and only look at 
the adjacent groups. However, we do not have that privilege in multiple samples. The idea 
behind the optimization in the single sample is to merge the mutations that have the same 
VAF and avoid calculations. So to implement the same idea in multiple samples, we need 
to merge the mutations that have the same VAF across all samples and collapse them into 
one group before performing the hierarchical clustering.  
In order to do that, we first compute the Euclidean distance between each pair of 
variants based on their VAFs in all samples. We then construct an incidence matrix and set 
the entry in row x and column y to 1 if the Euclidean distance between variants x and y is 
less than a threshold across all samples (the default value for the threshold in the algorithm 
is 0.01 but can be modified in the code). Using an undirected graph created from this 
incidence matrix, we search for the largest complete subgraphs and collapse variants 
belonging to each complete graph into a leaf-node in our initial hierarchical clustering step.  
To build the graph we take each mutation as a vertex, and we put an edge between two 
vertices if the value of element corresponding to the two mutations is 1.  Each "complete" 
subgraph represents a group of mutations in which all are inside a sphere with a diameter 
of the threshold value across all samples, meaning all of these specific mutations are closer 
to each other than the threshold value (Fig 5).  
  31 
The benefit of this approach is that in a single step, we can construct multiple 
clusters and reduce number of leaf nodes significantly, and we avoid calculating the 
unnecessary distances between the mutations among these clusters and other clusters. 
Because the number of leaf-nodes determines the computational complexity of a 












Figure 2.5: The incidence matrix and the corresponding undirected graph created from the 
distance matrix. In creating the graph, we merge the mutations from the biggest complete 
graph. For example, m5 also creates a complete graph with m8, but since the subgraph 
created with m6 and m7 has three mutations, we select that and keep m8 as a separate 
mutation, m5 and m8 are not merged in this step. 
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2.3 MAGOS Performance 
Discovering the clonal structure of cancer have always been a big challenge. Lack 
of accurate data, insignificant depth, and lack of ground truth are among the reasons that 
make it hard to design and tune algorithms and secondly evaluate any developed 
algorithm. Most of the previous studies have relied heavily on simulations. Either, clones 
are simulated from real germline mutations or completely simulating the reads with 
proposed models. Simulations are used to evaluate models and tune the parameters of the 
models. Although the simulations cannot precisely replicate real data, it is the best that 
can be done in the absence of real data with ground truth. Because of the levels of 
heterogeneity in tumor samples, it is costly to be able to capture all of the diversity in the 
sample. Ideally, in order to get the most accurate view of the tumor, we need to perform 
single-cell sequencing on a large number of cells from the single tumor, which has its 
constraints and practicality issues. Bulk sequencing is still the preferred approach. By 
using bulk sequencing, we need to sequence multiple samples from the tumor with high 
depth to capture an accurate view of the tumor structure.  
Recently, a few studies have tried to sequence a few ultra-deep sequencing 
samples to establish a high-quality data set to be used in genome sequencing analysis 
(Griffith et al. 2015). In Griffith et al., they have sequenced two samples from an AML 
patient up to 10000x coverage to get the most accurate mutation data. The problem with 
these kinds of studies is that the number of samples is limited, and it is not practical to 
have all the sequencing samples sequenced at that coverage. Of course, this study has 
provided us with a valuable evaluation dataset. As mentioned in chapter one, as the 
sequencing coverage increases, the variance of the clusters decreases, and clusters 
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become apparent, and clustering becomes trivial when the coverage is high enough. In 
this study, the data with the highest sequencing depth can be considered as the truth. 
Using the labels form the high coverage data, and map them back to the low coverage set, 
we can have the ground truth on the low coverage set.  
In this chapter, we present the performance of MAGOS on simulated single 
samples. We extensively tested MAGOS on simulated data with different depth and 
different clonal structure and tried to cover almost every clonal possibility. Next, we 
tested MAGOS on multiple simulated samples. We also ran SciClone and PyClone on 
each dataset to compare their result with MAGOS. Finally, we used the data published in 
Griffith et al. to compare the performance of MAGOS with SciClone and PyClone on 
three different coverages and showed that MAGOS performance is superior to the other 
methods. 
2.3.1 Simulating Subclones in Single Tumor Sample 
In here, we explain the down sampling approach that we used in order to generate 
the simulation data for the single sample evaluation. In each simulation, we create an 
artificial tumor sample containing two subpopulations sequenced at an average depth 
of 𝑒. Variants in each subpopulation are drawn from a pool that is the founding clone in 
the primary acute myeloid leukemia sample sequenced at >10,000x depth by Griffith et. 
Al (Griffith et al. 2015).  Because this sample has an estimated purity of 90.3% and the 
founding clone contains only heterozygous somatic mutations, the mean VAF of variants 
in this pool is 𝑢 = 0.451. To create a subclone containing 𝑚 variants with a mean VAF 
𝑣, we first draw 𝑚 random variants from the pool. For a given variant, there are 𝑒𝑟
0 
number of reads mapped to the reference allele and 𝑒𝑎
0 number of reads mapped to the 
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alternative allele in the pool. We down-sample these reads to the lower sequencing depth 
𝑒 according to Poisson distributions  
{










      
where  𝜂 = 𝑒/(𝑒𝑟
0 + 𝑒𝑎
0), and  𝑒𝑟 and 𝑒𝑎 are the number of reads mapped to the reference 
allele and to the alternative allele in the simulated tumor sample, respectively. Using this 
strategy, we generate two subclones each containing 𝑚 = 100 somatic variants and 
combine them to create an admixture, representing a single tumor sample with a two-
subclone structure. We vary the mean VAF 𝑣 of each subclone between 0.05 and 0.45 
and the overall sequencing depth 𝑒 at 30x, 60x, 100x, 200x, 300x, 500x. 
2.3.2 J Score 
The J score is a modification of the %GE value used by Miura et. al. to evaluate 
subclone discovery methods (Miura et al. 2018). However, the J score accommodates 
subclone sizes (i.e. number of variants in each subclone) when quantifying the 
similarities between two sets of clusters. Specifically, we denote 𝑇 as a set of clusters 
representing the ground truth, and 𝐷 as a set of clusters representing predictions. For each 





where 𝐴 is the set of variants defining cluster 𝑡, and 𝐵 is the set of variants defining 
cluster 𝑑. After all truth clusters are matched, if there remain unmatched clusters in 𝐷, we 
use the Jaccard Index to find their most similar clusters in 𝑇. After finding the best 
matched pair for all truth clusters and all predicted clusters, we compute the 𝐽 score as 





where 𝐼𝑝 is Jaccard Index of the 𝑝
𝑡ℎ pair, and 𝑛𝑝 is the number of variants in the truth 
cluster involved in this pair. J score takes a value between 0 and 100, in which 0 means 
no overlap between any truth clusters and any predicted clusters, and 100 means perfect 
matches between truth and predictions. 
2.3.3 Performance on Simulated Datasets 
2.3.3.1 Performance on simulated single tumor samples  
In evaluating a model, specifically when there is no ground truth, using 
simulations is the most common approach. In evaluating MAGOS, we needed to 
determine how sensitive the algorithm is to depth, the difference between subclones, and 
number of mutations. In order to do that, we simulated a huge number of data sets that 
could give us the necessary insight into how good the algorithm can perform and how 
much it could be trusted. This could be shown in comparison to other popular packages, 
e.g. SciClone and PyClone. We ran both of these methods on each dataset and compared 
their results. At the first part, the goal is to estimate the lower bound of sequencing depth 
and difference of mean VAFs between the clusters that MAGOS can detect.  
To estimate the lower bound of sequencing depth and difference of mean VAFs 
(∆?̅?) between subclones that can be detected by MAGOS, PyClone, and SciClone, we 
simulated tumor samples with a simple two-population structure. The Griffith et al. study 
has sequenced a primary leukemia sample at various depths from 60x to over 10,000x 
(Griffith et al. 2015). This sample had an estimated purity of 90.3% and consisted of 
1,343 somatic variants in the founding clone. The distributions of VAFs of these variants 
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confirmed that the variance of VAFs was negatively correlated with the sequencing depth 
(Pearson correlation coefficient= –0.54, correlation test p-value=0.02). Using these 
variants as a pool, we randomly drew two populations each containing 100 variants. We 
then adjusted the ?̅? of each population between 0.05 and 0.45 with an interval of 0.05, 
combined these two populations and simulated read counts at an average sequencing 
depth of 30x, 50x, 100x, 200x, 300x and 500x via a Poisson-based down-sampling 
procedure which is discussed later in this chapter. For each combination of ?̅? values and 
sequencing depth, we created 10 artificial admixtures. To quantify decomposition 
accuracies, we computed a weighted Jaccard index (J) that considered both the number of 
clusters identified and the assignment of variants. A J score takes a value between 0 and 
100, with 100 indicating a perfect match between true compositions and inferred 
compositions. The J score is discussed in more details later in this chapter. 
We first examined admixtures in which the ?̅? of one population was 0.45 
representing a founding clone and the ?̅? of the other population was lower than 0.45 
representing a derived clone. We presented three examples to illustrate different 
decomposition results of these methods. In an admixture with a ∆?̅? = 0.2 sequenced at a 
30x depth, the distributions of VAFs of the two populations showed substantial overlaps 
covering a continuous spectrum of VAFs from 0.09 to 0.85 (Fig. 6). While MAGOS 
found the correct number of clusters, PyClone and SciClone reported excessive clusters, 
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Figure 2.6: Performance of MAGOS, PyClone and SciClone on simulated single tumor 
samples, consisting of two subclones. The scatter plots show two simulated clusters of 
variants in a tumor sample. The mean VAFs of the two clusters are 0.45 and 0.20 and the 
average depth is 30x. The scatter plots is the truth assignment of the mutations. The blue 
being the clone and the orange cluster being the subclone. MAGOS was able to detect 
two clusters whereas SciClone only detected one cluster. PyClone as well, found one 
main cluster, but it detected a few clusters with only one mutation assigned to them.  
 
At the 300x depth, the same admixture produced well-separated distributions of 
VAFs (Fig. 7). Both MAGOS and SciClone then found two clusters correctly. PyClone 
however still reported more than two clusters with many clusters containing one or two 
variants. As we see as the depth increases, the clustering task becomes easier as the 
distance between the clusters becomes apparent.  
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Figure 2.7: Performance of MAGOS, PyClone and SciClone on simulated single tumor 
samples, consisting of two subclones. The scatter plots show two simulated clusters of 
variants in a tumor sample. The mean VAFs of the two clusters are 0.45 and 0.20 and the 
average depth is 300x.The blue being the clone and the orange cluster being the subclone. 
MAGOS and SciClone were able to detect two clusters. PyClone as well, found two main 
cluster, but it detected a few clusters with only one mutation assigned to them. PyClone 
also failed to perform the correct assignment of the mutations belonging to the main 
clusters.  
 
When we reduced the difference between the subclones frequencies (∆?̅?) to 0.05, 
it was extremely challenging to divide the two populations even at the 300x coverage 
(Fig. 8). In this case, SciClone reported one cluster and PyClone reported three main 
clusters, respectively. Although MAGOS successfully recognized the existence of two 
clusters, it assigned only 75% of the variants to the correct cluster.  
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Figure 2.8: Performance of MAGOS, PyClone and SciClone on simulated single tumor 
samples, consisting of two subclones. The scatter plots show two simulated clusters of 
variants in a tumor sample. The mean VAFs of the two clusters are 0.45 and 0.4 and the 
average depth is 300x.The blue being the clone and the orange cluster being the subclone. 
MAGOS was able to detect two clusters with 75% correct assignment. SciClone found 
only one cluster. PyClone, found three main clusters, but it detected a few clusters with 
only one mutation assigned to them.  
 
In the next step, we wanted to determine what is the minimum VAF difference 
between the clusters that each algorithm can achieve 80% minimum accuracy in different 
depths. Using J >80 as the accuracy threshold, we recorded the minimum ∆?̅? value 
between the two populations at a given sequencing depth for each method. The advantage 
of MAGOS was the most prominent at the depths of 30x – 50x (Fig. 9). In these 
simulations, MAGOS could produce accurate decompositions with ∆?̅? as low as 0.25. 
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PyClone required a ∆?̅? of at least 0.35. SciClone could not achieve J >80 at any level 
of ∆?̅?. MAGOS retained the leading position till the sequencing depth increased to 200x, 
beyond which both MAGOS and SciClone could decompose the admixtures equally well. 














Figure 2.9: Minimum ∆VAF of two subclones that can be decomposed with an accuracy 
J score >80 by each method. Broken tops on bars indicate J scores >80 cannot be 
achieved. 
 
Next, we examined the decomposition accuracies of all admixtures. The J score of 
all three methods was positively correlated with the ∆?̅? value (linear regression 
coefficients for MAGOS, PyClone and SciClone are 1.30, 1.03 and 0.87, respectively, all 
p-values <10-12). The J score was positively correlated with the sequencing depth for 
MAGOS and SciClone (coefficients are 0.08, 0.15, respectively, p-value <10-16), but not 
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for PyClone (coefficient=0.006, p-value=0.51). At the 30x depth, MAGOS could achieve 
an average J score ≥ 80 when  ∆?̅? ≥ 0.25 (Fig. 10). In a total of 100 such admixtures, the 
average J score of MAGOS was 86.6, which was significantly better than that of PyClone 
(73.7, t test p-value=0.008) and SciClone (54.4, p-value=3.5x10-8). As the depth 
increased to 300x, MAGOS could achieve an average J score ≥ 80 when  ∆?̅? ≥ 0.15 (Fig. 
11). In a total of 210 such admixtures, the average J score of MAGOS was 97.2, which 
was significantly better than that of PyClone (64.9, t test p-value=2x10-8) but slightly 
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Figure 2.10: Number of reported clusters (upper triangle) and J scores (lower triangle) at 
sequencing depths of 30x. Displayed values are averages of 10 simulations. Perfect 












Figure 2.11: Number of reported clusters (upper triangle) and J scores (lower triangle) at 
sequencing depths of 300x. Displayed values are averages of 10 simulations. Perfect 
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2.3.3.2 Performance on simulated multiple tumor samples  
To evaluate the performance of MAGOS on delineating complicated subclonal 
structure embedded in multiple samples from an individual tumor, we cannot use the 
simulation we used in the previous section. Because we need to construct more 
complicated structures. For this matter, we used an established method (El-Kebir et al. 
2015) to simulate the admixtures.  
The number of sequenced samples from a patient is very important in detecting 
the clonal structure and as the number of samples increases the accuracy of the detected 
structure increases significantly. In our multiple sample simulations, we generated set of 
simulations for two, three and four samples separately.  
For the two samples simulations, each simulation set contains 200 variants 
distributed among 3 subclones, and 10 replicates were generated at sequencing depth of 
30x, 50x, 100x and 300x each. Across all depths, MAGOS consistently outperformed the 
other two methods (Fig 12). The largest improvement was at 30x depth where SciClone 
and PyClone had a J score of 0.66 and 0.78, respectively and MAGOS had a J score of 
0.82 (paired t-test p-value<10-4). MAGOS remained at the leading performance at the 
sequencing depths increased to 50x and 100x (p-value<0.05). As the sequencing depth 
reached 300x, SciClone a performed equally well as MAGOS, achieving similar mean J 
scores of 0.95. Interestingly, although all three methods showed better performances at 
higher sequencing depth, PyClone was the least affected.  
 
 




Figure 2.12: Performance on simulated two tumor samples, each consisting of three 
subclones. Accuracies of different methods tested on tumors sequenced at depth from 30x 
to 300x. Asterisks indicate a significant better performance of MAGOS as compared to 
the other two methods. 
 
 Similar to the two sample case, for three samples and four samples cases and for 
each sequencing depths of 30x, 50x, 100x and 300x, we simulated 10 different set of 
simulations, each set contains 200 variants distributed among 3 subclone. Therefore, for 
three sample and four sample case, we simulated 40 simulations each. 
 In both three and four samples, on low coverage, MAGOS consistently performs 
better than both PyClone and SciClone. As the depth is increased, SciClone’s performance 
improves more than PyClone, but does not get better than MAGOS. MAGOS consistently 
performs better than all the other two.  
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Figure 2.13: Performance on three tumor samples, each consisting of three subclones. 
Accuracies of different methods tested on tumors sequenced at depth from 30x to 300x. 
Asterisks indicate a significant better performance of MAGOS as compared to the other 
two methods. 
 
Figure 2.14: Performance on four tumor samples, each consisting of three subclones. 
Accuracies of different methods tested on tumors sequenced at depth from 30x to 300x. 
Asterisks indicate a significant better performance of MAGOS as compared to the other 
two methods. 
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2.3.4. Performance on real-world sequencing data 
In the Griffith et al. study (Griffith et al. 2015), they sequenced the primary tumor 
sample and the relapse tumor sample of an individual with AML. The goal of the study 
was to optimize cancer genome sequencing analysis. They claimed that current 
sequencing strategies are inadequate on complex tumors. More importantly, they 
presented a comprehensively sequenced and validated dataset to be used as a resource for 
the community. They performed whole-genome sequencing of the tumor to depths 
greater than 300x. They also performed targeted sequencing up to 10000x coverage. They 
performed extensive filtering and manual review on the mutations to produce a set of 
1337 high quality mutations. On these set of mutations, they published the sequencing 
experiment results on them. The resulting set had read counts for this selected set from 
different range of depths, from low coverage to deeply sequenced. For our use, we used 
this set of mutations, compared the MAGOS’s performance on this set on the different 
coverages, and compared it to SciClone and PyClone. We showed that MAGOS is able to 
detect acceptable clonal structure on this set, even on the low coverage reads.  
We used the ultra-deep sequencing data published by Griffith et.al to assess the 
accuracy and reproducibility of MAGOS and the other two methods. This dataset 
contains 1,337 high-quality somatic SNVs detected in a primary sample and a relapsed 
sample from a patient with acute myeloid leukemia. Each sample was sequenced at up to 
10,000x depth for validation that represents the most comprehensively sequenced tumor. 
Although the true subclonal structures of these samples are unknown, we followed the 
authors’ suggestion and used clusters detected at highest depths as the benchmark to 
evaluate clusters found at lower depths (data at 30x, 60x and 300x were available). The 
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“best truth” consisted of five clusters with high confidences and two clusters with low 
confidences.  
 At the depth of 300x, MAGOS, PyClone and SciClone performed equally well, 















Figure 2.15: Performance on empirical data of two samples (primary tumor and relapsed 
tumor) from the same patient. Scatter plots show VAFs of variants sequenced at average 
depths of 300x. Dots of the same color are variants assigned to the same cluster by each 
method. Shaded ellipses represent “true” clusters inferred from data at ~10,000x 
sequencing depth. Radiuses of an ellipse correspond to 2 standard deviations of VAFs of 
variants belonging to a true cluster. 
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When the depth drops to lower than 60x, VAFs of these subclones showed large 
overlaps. However, MAGOS was still able to decompose the structure correctly, 
reporting six clusters. SciClone had great difficulties in separating overlapping clusters 
and reported only 3 subclones. Results from PyClone was similar to MAGOS but 























Figure 2.16: Performance on empirical data of two samples (primary tumor and relapsed 
tumor) from the same patient. Scatter plots show VAFs of variants sequenced at average 
depths of 60x. Dots of the same color are variants assigned to the same cluster by each 
method. Shaded ellipses represent “true” clusters inferred from data at ~10,000x 
sequencing depth. Radiuses of an ellipse correspond to 2 standard deviations of VAFs of 
variants belonging to a true cluster. 
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At the depth of 30x, MAGOS was the only method reporting the correct number 
of clusters and assigning variants to the correct cluster with high accuracies. SciClone 
reported results similar to 60x. PyClone added more than 10 small-interspersed clusters 















Figure 2.17: Performance on empirical data of two samples (primary tumor and relapsed 
tumor) from the same patient. Scatter plots show VAFs of variants sequenced at average 
depths of 30x. Dots of the same color are variants assigned to the same cluster by each 
method. Shaded ellipses represent “true” clusters inferred from data at ~10,000x 
sequencing depth. Radiuses of an ellipse correspond to 2 standard deviations of VAFs of 
variants belonging to a true cluster. 
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2.3.5. Computational Efficiency of MAGOS 
 Computational speed and efficiency becomes important when analyzing large 
number of samples and the combination of accuracy and efficiency is critical in clinical 
settings. Although, these algorithms are used in research mostly but in designing 
pipelines, it is critical to be computationally efficient. In this section, we compared 
computational speed of MAGOS to SciClone and PyClone in three different settings. We 
evaluated the speed sensitivity of MAGOS to number of mutations, depth of coverage 
and number of samples. 
 At first, we tested all three algorithms on simulated datasets with 2 samples, fixed 
depth of 100x and varying number of mutations (50, 100, 300, 500 and 1000 mutations). 
For each setting, we simulated 10 simulation sets and recorded the computational speed 
of the three (Fig. 2.18). As MAGOS is significantly faster than SciClone and PyClone 
across all number of mutations.  
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Figure 2.18: Computational efficiency comparisons tested on simulated tumors. (A) Each 
tumor has two samples and each sample contains 50 to 1,000 mutations sequenced at 
100x depth. 
 
 Then we tested the speed against the sequencing depth of the data. We fixed 
number of samples and the number of mutations and varied the depth from 30x to 1000x. 
In this situation as well, as the depth got larger, MAGOS and SciClone performed faster. 
The reason for this is that with increasing depth the clusters get denser, and the clustering 
task becomes easier for MAGOS and SciClone. However, PyClone is not sensitive over 
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Figure 2.19: Each tumor has two samples and each sample contains 100 mutations 
sequenced at depth from 30x to 1,000x.  
 
At last, we tested the speed over different number of samples. We fixed the depth 
(=100x) and number of mutations (=200) and simulated data for 1 to 4 samples. As 
expected, for all three algorithms, speed decreased by adding additional samples, because 
number of required computations increased (Fig. 2.20).   
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Figure 2.20: Each tumor has 1 to 4 samples and each sample contains 100 mutations 
sequenced at 100x depth. 
 
 
2.4 Application to TCGA Data 
 The TCGA data is valuable source of data from different cancer types as well as 
clinical data. By executing MAGOS on each sample for 33 different cancer types, we 
detected the number of clones/subclones in each sample. From the clinical data and clonal 
data, we analyzed the association between the number of subclones and the survival of the 
patient. In some of the cancer types, we were able to find strong association between 
number of clones and the survival of the patient, meaning the number of subclones 
identified by MAGOS has prognostic power on these cancer types. On the other hand, none 
of the reported features had any prognostic power on the survival of the patient. In the 
coming sections, we discuss out significant findings.  
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2.4.1. Liver Hepatocellular Carcinoma (LIHC) 
We applied the MAGOS method to whole-exome sequencing data of 331 liver 
hepatocellular carcinoma samples from the TCGA project. The majority (79.2%) of these 
tumors contained 3 or 4 subclones (Table 2.1). Using Cox proportional hazard 
regressions, we tested if the number of subclones in a tumor was significantly associated 
with patient overall survival via age at diagnosis, sex and tumor stages as covariates. We 
found a significant association among tumors of stage III (p-value=0.01, HR=1.67, Fig. 
2.21). For comparisons, the number of mutations in a tumor is not a significant 
prognostic factor among these tumors (p-value=0.44). Therefore, the subclone number is 
a novel prognostic factor for stage-3 liver cancers that is independent of age at diagnosis, 
sex and total number of mutations. In Fig. 2.21 it is observed that the number of 
subclones are negatively correlated with the survival. The patients with fewer subclones, 
tend to survive longer. 
 
Table 2.1: the distribution of cluster counts across tumor stages in LIHC 
 
 
  NUMBER OF SUBCLONES IN A TUMOR   
 













I 0 25 66 62 13 0 166 50.2% 
II 1 7 38 28 6 0 80 24.2% 
III 0 9 35 30 6 1 81 24.5% 
IV 0 1 1 2 0 0 4 1.2% 
subtotal 1 42 140 122 25 1 
  
 
 0.3% 12.7% 42.3% 36.9% 7.6% 0.3%   




Figure 2.21: Kaplan-Meier plot of liver cancers at stage III. Tumors were stratified into 
groups based on the number of subclones. 
 
2.4.2. Adenoid cystic carcinoma (ACC) 
In Adenoid cystic carcinoma, we discovered some interesting relationships 
between the number of subclones and the survival. By performing the same analysis, we 
discovered that the tumor stage and the number of subclones are correlated (p-value= 
0.0005, Table 2.2). In the survival plots, we can see that the number of subclones are not 
strongly associated with survival although by looking at the events after 6 months, the 
effect of number of subclones become significant. Although in the Cox proportional 
hazard regression analysis, tumor stage is the strongest prognosis factor and not the 
cluster count.  




Figure 2.22. Kaplan-Meier plot of ACC. Tumors were stratified into groups based on the 
number of subclones. 
 
Table 2.2. Counts of subclones across different tumor stages in ACC 
       NUMBER OF SUBCLONES IN A TUMOR 
 
 












I 5 3 1 0 9 11.4% 
II 4 19 11 3 37 46.8% 
III 0 6 7 3 16 20.3% 
IV 0 6 7 2 15 19.0% 
subtotal 9 34 26 8  
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2.4.3. Ovarian Cancer (OV) 
 In the analysis of 272 ovarian cancer primary tumor samples from TCGA, we 
discovered that the age at diagnosis has the most prognostic power among the available 
features (p-value=0.0017). Although, by using the Cox proportional hazard model, 
number of detected subclones by MAGOS also has significant effect on survival of the 
patient (p-value=0.046). Since tumor stages is not reported, the only important features 
are age at diagnosis and number of subclones whereas number of mutations is not 
significant (p-value= 0.32). In ovarian cancer, MAGOS detected 1, 2, 3, 4, 5 and 6 
clones. In Fig. 2.23, we look at the survival plots for subclones greater than 4 and 
samples with fewer than 4 subclones. Interestingly, in OV, if the number of subclones are 
more than 3, the patients tend to survive longer.  
 
 
Figure 2.23. Kaplan-Meier plot of OV. Tumors were stratified into groups based on the 
number of subclones. 
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2.4.4 Thymoma (THYM) 
The analysis of THYM, showed that the number of subclones detected by 
MAGOS is the most promising feature in predicting survival of the patient. In the Cox 
proportional hazard model, number of subclones, is the most significant feature (p-
value=0.045). Interestingly, age at diagnosis, gender, and number of mutations do not 
have any significant prognosis (p-values= 0.46, 0.54, 0.1 respectively). The survival plot 
also indicates this prognosis power. Patients with fewer number of subclones tend to live 
longer.   
 
 
Figure 2.24. Kaplan-Meier plot of THYM. Tumors were stratified into groups based on 




  60 
2.4.5 Other Cancers 
 By analyzing the results from MAGOS on the other cancer types, we were not 
able to find significant association between survival and the number of subclones as 
strongly as the LIHC, THYM, ACC and OV. Although, in other cancer types we were 
able to detect the association if we looked at a specific subset of the data. In this 
approach, we were able to see the difference in survival curves at the later years, but the 
effect was not significant overall. We were able to see significant effect when we filtered 
the patients based on the minimum survival time. For example, in rectum 
adenocarcinoma, there is a significant difference between the survival rates of the 
patients that have greater than or equal to four subclones vs the patients with fewer than 
four subclones if we only look at the patients that remained in the study after 6 months 
(Fig. 2.25).  
 
Figure 2.25. Kaplan-Meier plot of READ. Tumors were stratified into groups based on 
the number of subclones. 
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We observed a similar trend in GBM, ESCA, CESC, HNSC, KIRP and LGG. We  
were not able to further derive any solid conclusions on the effect of cluster count on 
survival. In other cancer types, even the survival curves did not show any meaningful 
information.  
2.5 Discussion 
Cancer, as an evolutionary process, is born with a heterogeneous and dynamic 
nature (Nowell 1976; Greaves and Maley 2012). Precision identification and intervention 
of cancers shall consider the past, present and future of each tumor. With NextGen 
sequencing technologies, we can now catch snapshots of this process and potentially 
reconstruct the evolutionary history and trajectory of a tumor (Griffith et al. 2015; Ding 
et al. 2012; Landau et al. 2013; Gerlinger and Swanton 2010; Fisher, Pusztai, and 
Swanton 2013). While single-cell sequencing is a promising technology to examine the 
genetic compositions of individual cells, uneven genome coverage, low accuracy of 
variant calls and prohibitive cost limit its usage in subclonal investigations (Ma, Ennis, 
and Aparicio 2012; Sims et al. 2014; Andor et al. 2014; Navin et al. 2010). The majority 
of current studies and likely many others in the near future rely on bulk sequencing of 
mixed tumor cells and computational decomposition to identify variants that occur and 
evolve together. Several challenges emerge in these analyses.  
First, sequencing depth is a key factor affecting the accuracy of identified 
subclones (Sims et al. 2014). Shown in both the simulated and real-world data, as the 
sequencing depth drops, the centroid of each cluster remains unchanged while each 
cluster becomes more scattered, eventually leading to overlaps. Explicit modeling of this 
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correlation enables MAGOS to accommodate large variances at a lower depth. However, 
variants in overlapping areas are impossible to separate. Instead of using VAF cutoffs to 
create artificial borders, a more informative measure is the probability of each variant 
belonging to a specific clone, which MAGOS reports.  
Second, the difference of mean VAFs between subclones limits the power of 
distinguishing them. Increasing sequencing depth does not change the centroid of each 
cluster, thus helps little on detecting subclones with similar VAFs. Contrarily, additional 
samples from the same tumor helps segregate these clusters that are otherwise 
undiscernible. As MAGOS enables subclonal identifications from genomes sequenced at 
standard depths, the saved cost can be better invested on analyzing more samples. The 
benefit of sequencing additional samples is more evident at low sequencing depth, as 
shown in our test of PyClone. PyClone performs significantly worse than MAGOS when 
only a single sample is analyzed at low depth. However, when analyzing 2 samples at 
depth 60x, PyClone results are similar to that from MAGOS.  
Third, as multiple samples from a tumor help identify segregating subclones and 
whole genome sequencing reveals noncoding variants, these additional data also increase 
the computational complexity, which in turn requests efficient algorithms. We optimized 
the efficiency of MAGOS that tested its CPU time using simulated tumors. We varied the 
number of samples for each tumor, the number of mutations in each sample and the mean 
sequencing depth. Across all configurations, MAGOS showed 3-20x acceleration as 
compared to SciClone and PyClone, making it a fast and reliable method for subclone 
decompositions. The identified clusters can be used for further analyses, such as tumor 
phylogenetic inferences. 
  63 
CHAPTER 3 
CANCER-TYPE SPECIFIC DRIVERS & PROGNOSTIC VALUES 
3.1 Introduction 
In tumor development, oncogenes (OGs) and tumor-suppressor genes (TSGs) 
work complementarily to promote and maintain abnormal cell growth (Morris and Chan 
2015; Weinberg 1993). OGs cause cancers through gain-of-function variants, whereas 
TSGs operate by loss of function. While there are a few well known OGs (e.g., RAS) and 
TSGs (e.g., TP53), it is fast becoming clear that the tumor-enabling activities of a gene is 
not the same for all types of cancers. Activities of driver genes depend strongly on their 
cellular contexts because of tissue specific organizations of cancer pathways(Schaefer 
and Serrano 2016; Schneider et al. 2017; Visvader 2011). Prediction of functional status 
of genes in different cancer types and cellular contexts is critical for not only 
understanding tumor biology, but also informing targeted therapies and drug repurposing 
(Morris and Chan 2015; Schneider et al. 2017; Sleire et al. 2017). 
Interestingly, only one computational method (20/20+) is available to predict OGs 
and TSGs (Tokheim et al. 2016). 20/20+ is an extension of the 20/20 rule in which OGs 
have >20% mutations causing missense changes at recurrent positions and TSGs have 
>20% mutations causing inactivating changes (Vogelstein et al. 2013). However, 
recurrent missense mutations are not a deterministic feature of OGs because these events 
can cluster at functionally neutral positions due to high mutational rates (Schaub et al. 
2018), and many TSGs harbor hotspots of inactivating missense mutations (Iacobuzio-
Donahue et al. 2004; M. L. Miller et al. 2015). Meanwhile, random mutational processes 
may introduce protein-truncating mutations (i.e., nonsense and frameshifting mutations) 
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into OGs, which increase in frequency via genetic drift with no significant impact on 
tumor fitness and mislead annotations (Lipinski et al. 2016; Mort et al. 2008; Schaub et 
al. 2018). Therefore, conventional ratiometric measures are inadequate to distinguish 
these two groups of genes. 
Because tumor development is an evolutionary process, cells carrying somatic 
mutations are under natural selection within tumors. The positive selection promotes 
advantageous genotypes that confer higher fitness to a tumor. The negative selection 
eliminates genotypes with adverse effects. Neutral evolution lets insignificant genotypes 
to drift up or down in frequency. In OGs, gain of functions may be achieved via missense 
mutations, which are expected to be positively selected. In contrast, protein-truncating 
mutations (e.g., nonsense mutations and frame-shifting mutations) often inactivate an OG 
and are detrimental to tumor fitness, resulting in negative selection. In TSGs, both 
protein-truncating mutations and missense mutations can be positively selected when 
they result in the loss of functions. Otherwise, they may drift neutrally or be even under 
negative selection if they disrupt essential biological functions.  For passenger genes 
(PGs) that do not have significant impact on tumor fitness, we expect that all mutations 
be under neutral selection (Sun et al. 2017; Williams et al. 2016). 
We tested whether the difference in evolutionary dynamics of missense and 
truncating mutations has sufficient signal and power to improve the detection of OGs and 
TSGs beyond that of ratiometric measures.  Such contrast is essential to distinguish TSGs 
deactivated by missense mutations from OGs activated by missense mutations, which is a 
challenging task for conventional ratiometric measures because hotspots of missense 
mutations are present in both cases. Furthermore, when activities of a gene vary across 
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cancer types, the direction and magnitude of somatic selection will change accordingly, 
enabling contextual classification of driver genes. 
Our analysis of 10,172 tumor exomes from the cancer genome atlas (The Cancer 
Genome Atlas 2013) project revealed significant differences in selective patterns of OGs, 
TSGs and PGs. Based on these patterns, we developed a computational method, named 
genes under selection in tumors (GUST) that integrates somatic selection of genes in 
tumor development, molecular conservation during species evolution, and conventional 
ratiometric measures to classify cancer genes in different tissues and organs.  
3.2 Existing Method: 20/20+ 
Next-generation DNA sequencing of the exome has detected hundreds of thousands 
of small somatic variants (SSV) in cancer. Distinguishing genes containing driving 
mutations rather than simply passenger SSVs from a cohort sequenced cancer samples 
requires sophisticated computational approaches. 20/20+ integrates many features 
indicative of positive selection to predict oncogenes and tumor suppressor genes from 
small somatic variants. The features capture mutational clustering, conservation, mutation 
in silico pathogenicity scores, mutation consequence types, protein interaction network 
connectivity, and other covariates (e.g. replication timing). 20/20+ uses ratiometric 
features of mutations by normalizing for the total number of mutations in a gene. 20/20+ 
uses Random Forest and used the set of OGs and TSGs identified by the original 20/20 
rule as a training set. Each gene was scored as the fraction of trees that voted for OG, 
TSG, or passenger gene. A driver score for each was calculated as the sum of the OG and 
TSG scores. Even though, 20/20+ extends the 20/20 rule and implements a more 
sophisticated model and predictive variables, but at its core, it still uses the ratiometric 
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measures. In our analysis, we show that integrating somatic selection of genes in tumor 
development improves the driver gene detection. We explain the GUST method, and 
compare the performance of GUST with 20/20+. 
3.3 GUST Method 
3.3.1 Curation of Cancer-Type Specific Functions of Driver Genes 
To train a random forest model, we needed cancer-type specific functional 
annotations of cancer genes. Because these annotations are not currently available, we 
conducted manual curations using two lists of genes with complementary information. 
The first list consisted of 36 OGs, 48 TSGs and 21 genes with dual OG/TSG roles 
annotated in the cancer gene consensus (CGC, version 87, (Sondka et al. 2018)). The 
tumor-activating or -suppressing roles of these genes have been confirmed with cancer 
hallmarks in experimental assays and are attributable to coding substitutions or indels 
(Hanahan and Weinberg 2011). The second list consisted of 235 computationally 
predicted driver genes assigned to specific cancer types (Bailey et al. 2018). These 
predictions were based on a meta-analysis of the TCGA samples with multiple 
computational programs. These two lists shared 70 genes. We then retrieved somatic 
mutations of these 70 genes from the TCGA project (The Cancer Genome Atlas 2013). 
For a gene to qualify as an OG in a specific cancer type, it needs to be annotated as an 
OG or a dual-role gene in the CGC, predicted as a driver in the meta-analysis of the 
matching cancer type, and display mutational hotspots in the corresponding TCGA tumor 
samples. For a gene to qualify as a TSG in a specific cancer type, it needs to be annotated 
as a TSG or a dual-role gene in the CGC, predicted as a driver in the meta-analysis, and 
have an overabundance of truncating mutations or missense mutations in the 
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corresponding TCGA tumor samples. For a gene to qualify as a PG in a specific cancer 
type, it needs to be predicted as a PG in the meta-analysis and shows no mutational 
hotspots nor overabundance of truncating mutations in corresponding TCGA tumor 
samples. Genes that did not meet these requirements were removed. The final collection 
consisted of 55 OG annotations, 174 TSG annotations and 304 PG annotations that 
involved a total of 50 known driver genes and 33 cancer types. 
3.3.2 Somatic Selection Features 
 Given a gene with somatic mutations reported in a collection of tumor samples, we 
denote the selection coefficient of missense mutations as ω, and the selection coefficient 
of protein-truncating (nonsense and frameshifting) mutations as φ. To account for 
differences in mutational rates, we consider seven substitution types (1: A→C or T→G, 
2: A→G or T→C, 3: A→T or T→A, 4: C→A or G→T, 5: C→G or G→C, 6: C→T or 
G→A at non-CpG sites, and 7: C→T or G→A at CpG sites), one insertion type and one 
deletion type. Based on the statistical framework proposed by Greenman et al. (Chris 
Greenman et al. 2006), the probability of observing these mutations is a product of 
multinomial distributions 
 
               (3.1)   
 
 
where sk, mk, nk , ik and fk are the observed numbers of synonymous, missense, 
nonsense, in-frame indel and frameshifting indel mutations in the kth rate category, 
respectively; Sk, Mk, Nk , Ik and Fk  are the corresponding expected numbers of changes 
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computed by saturated mutations, in which we introduced each possible single nucleotide 
mutation one at a time; and tk=sk+mk+nk+ik+fk is the total number of observed mutations. 
The values of log(ω) and log(φ) are determined by maximizing the log likelihood L and 
constrained within the range of [-5, 5]. The sign and absolute value of log(ω) and log(φ) 
indicate the direction and magnitude of somatic selection. Values around 0 indicate 
neutral somatic evolution.  
3.3.3 GUST Algorithm 
GUST is a random forest model that predicts the class label (OG, TSG or PG) of a 
gene based on 10 features (Table 3.1, Fig. 3.1). In addition to the log(ω) and log(φ) 
values, we also compute ratiometric measures to detect mutational hotspots and 
conservational measures to estimate substitutional rate across species. Specifically, given 
a gene and a set of somatic missense mutations detected in tumor samples, we applied 
density estimates with a rectangular kernel and a bandwidth of 5 protein positions to 
aggregate closely-spaced mutations into peaks and denoted the highest peak as the 
summit. To estimate evolutionary conservation of a gene, we downloaded multiple 
sequence alignments of 100 vertebrate species from the UCSC Genome Browser (James 
Kent et al. 2002), and computed the substitution rate of each protein position (Kumar et 
al. 2012; L. Liu and Kumar 2013). The average substitution rate over all positions 
measures the gene-level conservation. The average substitution rate over positions in a 
summit measures the conservation of a mutational hotspot. For a given gene/cancer-type 
pair in the curated annotations, we retrieved somatic mutations from the corresponding 
TCGA tumor samples and computed values of the 10 features. Using these training data, 
we constructed a random forest classifier with 200 trees. For each gene, this model 
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produces three probability scores of it being an OG, a TSG or a PG, respectively. It 
assigns the class label based on the highest probability score. For all predictions, GUST 
reports random forests probability score, sensitivity and specificity. For OG or TSG 
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Table 3.1: Features tested, removed and included in GUST random forest classifier  































Selection coefficient of missense 
mutations 
log(φ) 




Fraction of missense mutations 
over all mutations 
R.truncating 
Fraction of truncating mutations 
over all mutations 
R.peak 
Fraction of missense mutations 
under peaks 
R.summit 
Fraction of missense mutations 
under the highest peak 
C.summit 
Count of missense mutations 
under the highest peak 
R.length 




Mean substitution rate of all 
positions of the protein 
E.summit 
Mean substitution rate of 
positions under the highest peak  
Features tested, but not 
included in GUST 
log(ω) + log(φ) 
Sum of selection coefficient of 
missense and truncating 
mutations 
protein length Length of protein 
protein length before 
summit 
Position of summit divided by the 
length of protein 
R.summit / R.peak Ratio of R.summit and R.peak 
 
 
3.3.3.1 Feature Selection and Random Forest Classifier  
Each record in the training data involved one gene and one cancer type. For a 
given gene/cancer-type pair, we retrieved somatic mutations from the corresponding 
TCGA tumor samples and computed values of the 14 features. We then employed a 
backward selection procedure to identify the most informative features. We started with a 
baseline model by building a random forest classifier with 200 trees, in which the 
predictors included all 14 features and the response was class labels. For each gene, this 
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model produced three probability scores of it being an OG, a TSG or a PG, respectively. 
It assigned the class label based on the highest probability score. We computed the 
overall prediction accuracy via 10-fold gene-holdout cross-validations. We then removed 
one feature, built an alternative random forest model with the remaining 13 features and 
computed the cross-validation accuracy. Among these 13-predictor alternative models, 
we identified the one with the highest accuracy and set it as the new baseline. We 
repeated the above procedure to sequentially remove one feature at a time, and recorded 
the highest accuracy at each iteration (Fig 3.1). The highest accuracy was 0.923 that 
corresponded to two models, one using 10 predictors and the other using 11 predictors. 
We chose the 10-predictor model for GUST because adding the 11th feature did not 
improve the accuracy. For the 10-predictor random forests classifier, we built ROC 
curves for one-vs-rest predictions, extrapolated the values corresponding to the 
probability score and estimated the sensitivity and specificity associated with a 
prediction. 
To compute false discovery rates (FDR), we simulated passenger genes by 
randomly moving the observed mutations across genes. Given all mutations observed for 
a cancer type, we first stratify them by seven substitution types (1: A→C or T→G, 2: 
A→G or T→C, 3: A→T or T→A, 4: C→A or G→T, 5: C→G or G→C, 6: C→T or 
G→A at non-CpG sites, and 7: C→T or G→A at CpG sites), one insertion type and one 
deletion type. Within each stratum, we randomly moved the mutations across genes 
following a uniform distribution, which generated 18,810 simulated passenger genes. We 
then applied GUST to classify these genes. GUST misclassified 271 genes as OGs and 
432 genes as TSGs. We then used the scores of the misclassified OGs to build an 
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empirical null distribution of OGs. For a test gene predicted as an OG with a score s, we 
calculated the FDR as the fraction of simulated genes with a score ≥s. Similarly, we built 
an empirical null distribution of TSGs, against which FDR can be calculated for a test 
gene predicted as a TSG. 
3.4 GUST Results 
3.4.1 Different Selection Patterns of Cancer Genes  
For each gene/cancer-type pair in our manual annotations, we retrieved somatic 
mutations in the matching tumor samples from the TCGA project, and computed the 
somatic selection coefficients. We found that missense mutations in OGs were under 
stronger positive selection than in TSGs, as the mean log(ω) was 4.18 and 1.68, 
respectively (P < 10-10, Fig. 3.2). In contrast, protein-truncating mutations showed 
positive selection in TSGs (mean log(φ) =4.08), but negative selection in OGs (mean 
log(φ) =  –3.25, respectively). The effect size of the differences observed is very large, 
and the P values highly significant (P < 10-8). The selection measures observed on PGs 
were close to zero (mean log(ω) =0.60 for missense and mean log(φ)= –0.28 for nonsense 
mutations). Therefore, TSGs, OGs, and PGs show significant evolutionary differences. 
The distribution of log(φ) values of PGs had two peaks. The largest peak located close to 
0, consistent with the expected neutral selection of PGs. The second peak located close to 
–5, indicating that loss of function of these PGs is detrimental to tumor growth. 
Interestingly, many genes in the second peak are established TSGs in other cancer types 
where loss of their functions is beneficial to tumors. For example, the BCOR gene 
regulates apoptosis in stomach cancer and had overabundant truncating mutations (The 
Cancer Genoma Atlas 2013). However, this gene was depleted of truncating mutations in 
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melanoma (Fig. 3.3). Such contrast suggested that although disabled TSGs promote 
tumor growth in certain cellular contexts, maintaining their activities may be essential for 
tumor development in other contexts. We then examined the joint distributions of log(ω) 
and log(φ) values and found that somatic selection patterns reflected the contextual 
activities of a gene (Fig. 3.4). For example, the PIK3CA gene had high log(ω) values and 
low log(φ) values in bladder cancers, breast cancers and colorectal cancers, consistent 
with its well-known OG role. The log(ω) and log(φ) values of this gene were close to 
zero in melanoma, indicating lack of a role resulting in neutral patterns. Recently, the 
passenger role of PIK3CA in melanoma has been proposed in a study that shows 
PIK3CA-mutated melanoma cells rely on cooperative signaling to promote cell 
proliferation and PI3K inhibitors do not repress tumor growth in the absence of other 
activating driver genes in melanoma (Silva et al. 2017). 
For TSGs, such as TP53, their high log(φ) values occupied spaces distant from 
OGs in the distribution plot (Fig. 3.4). As discussed earlier, TSGs with hotspots of 
missense mutations, such as the FBXW7 gene in uterine carcinosarcoma (Fig. 3.5) are 
challenging to distinguish from OGs using ratiometric methods. Based selection 
measures (log(ω)=5.0, log(φ) =3.9), this gene is unambiguously separated from OGs 




























Figure 3.3.  Positional distribution of somatic mutations of the BCOR gene in stomach 
cancer and in melanoma. Vertical lines represent frequencies of various type of mutations 
at a given position. Synonymous, missense and truncating mutations are represented by 
green, blue and red lines, respectively. Gray lines are density curves.   
  





















Figure 3.4. Scatter plot of log(ω) and log(φ) values. Shades of hexagon bins represent the 


















Figure 3.5. Positional distribution of somatic mutations of the FBXW7 gene in uterine 
carcinosarcoma   
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3.4.2 Performance of the GUST Method 
We trained a random forest classifier (GUST) using the 10 features of the curated 
genes. Via 10-fold gene-holdout cross-validations, the testing accuracy of GUST was 
0.92. As a comparison, the accuracy of 20/20+ on the entire training dataset was 0.86. To 
calculate traditional performance metrics, we converted three-class predictions to binary 
predictions by contrasting one class with the other two classes combined, i.e., one-vs-rest 
predictions. In all categories, GUST showed better or comparable performance than 
20/20+. The largest improvements were on the precision of identifying OGs and TSGs, 
which increased from 0.78 – 0.82 in 20/20+ to 0.85 – 0.92 in GUST (Table 3.2). The 
receiver operating characteristic (ROC) curves reconfirmed the superior performance of 
GUST (Fig. 3.6). Compared to 20/20+, GUST had a significantly higher area under the 
curve (AUC) value of the PG-vs-rest ROC curve (0.97 vs. 0.94, DeLang’s test 
P=0.0008), and a significantly higher AUC value of the TSG-vs-rest ROC curve (0.97 vs. 
0.93, P=0.001). However, the AUC values of the OG-vs-rest ROC curves were not 
significantly different between these two methods (0.99 vs. 0.97, P=0.21).  
To evaluate the concordance of GUST classifications with other methods that predict 
cancer drivers but do not distinguish OGs and TSGs, we computed a driver score by 
adding the OG and TSG scores of each gene. The TCGA PancanAtlas consortium 
reported a collection of putative driver genes based on consensus predictions from 12 
computational methods (Bailey et al. 2018). We first examined the 510 gene/cancer-type 
pairs (204 unique genes) predicted as drivers by ≥2 methods. In this permissive list, 
GUST predicted 373 pairs (73.1%, 145 unique genes) as drivers. We then examined the 
283 gene/cancer-type pairs (109 unique genes) predicted as drivers by ≥3 methods. In this 
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more stringent list, GUST predicted 254 pairs (89.8%, 96 unique genes) as drivers. These 
results showed that drivers predicted by GUST had a high agreement with existing 
methods while providing additional OG/TSG classifications. 






Positive OG, TSG OG TSG 
Negative PG PG, TSG PG, OG 
GUST 
TPR 0.93 0.84 0.93 - 
TNR 0.94 0.98 0.95 - 
PPV 0.92 0.85 0.9 - 
NPV 0.95 0.98 0.96 - 
ACC 0.94 0.97 0.94 0.92 
AUC 0.97 0.99 0.97 0.98* 
20/20+ 
TPR 0.90 0.95 0.86 - 
TNR 0.85 0.97 0.90 - 
PPV 0.82 0.78 0.81 - 
NPV 0.92 0.99 0.93 - 
ACC 0.88 0.97 0.89 0.86 









Figure 3.6. ROC curves of one-vs-rest predictions for GUST and for 20/20+ 
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To measure the importance of each predictor in the random forest model, we 
computed the mean decreased Gini index by per-muting out-of-bag samples (Louppe et 
al. 2013). The most informative predictors are the selection coefficients and fraction of 
truncating mutations, followed by the selection coefficient and fraction of missense 
mutations (Fig. 3.7). Interestingly, evolutionary conservation was not very informative, 
which may be because a vast majority of drivers are known to occur at highly conserved 








Figure 3.7. Variable importance of each feature in the random forest model. 
 
Although recurrence among patients has been taken as a surrogate of mutations 
under functional selection, recent investigations have shown that passenger hotspot 
mutations are common (Buisson et al. 2019; Hess et al. 2019). For example, multiple 
samples of various cancer types harbored a C->T or C->G mutation at position 931 of the 
MB21D2 gene (Fig. 3.8). Buisson et al. discovered that this mutational hotspot is due to 
its location in a hairpin loop susceptible to mutagenesis and functions as a passenger 
(Buisson et al. 2019). GUST analysis confirmed that the selection pattern of this gene 
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was consistent with neutral evolution in individual cancer types and in the combined 
samples (Fig. 3.9). Thus, GUST predicted the MB21D2 gene as a PG correctly. This 
demonstrated the effectiveness of quantifying the contribution of genetic alterations to 















Figure 3.8. Positional distribution of somatic mutations of the MB21D2 gene. Mutations 
were combined from tumor samples of bladder cancer, cervical cancer, head and neck 
cancer, lung adenocarcinoma, and lung squamous cell carcinoma. A mutation hotspot is 
located at coding position 931 that corresponds to protein position 311. 
  



















Figure 3.9. Selection coefficients estimated for the MB21D2 gene in individual cancer 
types (dots) and for combined samples (cross). Broken lines are the mean selection 
coefficient of all genes analyzed using all TCGA samples. Shaded areas are the 95% 





3.4.3 Application to TCGA Data 
We retrieved somatic mutations from whole-exome sequencing data of 10,172 
TCGA tumor samples spanning 33 cancer types. We then removed low-quality 
mutations, hyper-mutated or hypo-mutated samples, genes with fewer than 4 protein 
altering mutations, and genes mutated in <2% of tumors which we will discuss below. 
We applied GUST to the remaining 9,663 samples. We predicted 161 OGs of which 98 
were unique genes in 29 cancer types. We also predicted 331 TSGs of which 179 were 











Figure 3.10. Number of common and rare OGs and TSGs found in each cancer type. 
3.4.3.1 Preprocessing TCGA data  
The TCGA project provides whole-exome sequencing data of 10,172 tumor 
samples representing 33 cancer types (The Cancer Genoma Atlas 2013). We retrieved 
somatic mutations called by the GATK/MuTect pipeline (Cibulskis et al. 2013) against 
the hg38 human reference genome from the Genomic Data Commons (GDC) data portal 
(Grossman et al. 2016). We removed low-quality mutations and kept single nucleotide 
substitutions causing synonymous, missense or nonsense changes, and indels causing in-
frame or frame-shifting changes of the encoded proteins. Due to the rare occurrences 
(<1%) and low confidence (Jian, Boerwinkle, and Liu 2014) of predicted splice site 
mutations, we did not include these mutations in the analysis. We computed the 
mutational load of a tumor as the number of mutations it contained. For each cancer type, 
we removed samples with mutational loads outside the 1.5 interquartile range below the 
first quartile or above the third quartile, respectively. A total of 194 hypo-mutated and 
315 hyper-mutated were removed. For each cancer type, we removed less frequently 
mutated genes that had fewer than 4 protein-altering mutations or were mutated in less 
than 2% of tumor samples to avoid non-convergence problems during maximum 
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likelihood estimations of selection coefficients. Because uterine corpus endometrial 
carcinoma had a significantly higher mutational load than the other cancer types (z test p-
value=0.017), we increased the threshold for this cancer type to remove genes mutated in 
less than 5% of tumor samples. 
3.4.3.2 Novel Driver Genes  
The GUST-predicted drivers consisted of 55 putative OGs and 97 putative TSGs 
that were classified as PGs in the CGC database (Sondka et al. 2018). Most (81.7%) of 
these new putative drivers were annotated in only one cancer type and had low 
probability scores. To estimate the confidence of each prediction, we computed the 
sensitivity and specificity of each one-vs-rest prediction based on the ROC curves. We 
then derived a list of high-confidence drivers consisting of 22 OGs with OG-vs-rest 
specificity ≥0.99 and 74 TSGs with TSG-vs-rest specificities ≥0.99, all of which had a 
PG-vs-rest sensitivity ≥0.99.  This short list of high-confidence drivers included two 
novel OGs and 28 novel TSGs not annotated in the CGC. The two novel OGs (CNOT9 in 
melanoma and GTF2I in thymoma) had single mutational hotspots disrupting highly 
conserved protein positions (Fig. 3.11, Fig 3. 12). The GTF2I mutant stimulates cell 














Figure 3.11. Positional distributions of somatic mutations of CNOT9 in melanoma. 
Evolutionary conservation of each position, measured as number of substitutions per 









Figure 3.12. Positional distributions of somatic mutations in GTF2I in thymoma. 
Evolutionary conservation of each position, measured as number of substitutions per 
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All of the novel TSGs had an overabundance of truncating mutations (FIG 3.15). 
For example, frameshifting mutations in SOX9 were observed in 40 colon cancers (Fig. 
3.13). As an atypical tumor suppressor, SOX9 has been shown to interact with nuclear β-
catenin. Inactivation of SOX9 causes loss of inhibition of the oncogenic Wnt/β-catenin 
signaling pathway and is associated with patient survivals (Prévostel et al. 2016). Some 
novel TSGs harbor mutational hotspots. For instance, the N583fs frameshifting mutation 
in BMPR2 introduced premature stops of protein synthesis and was observed in nine 
stomach adenocarcinomas (Fig. 3.14). We searched the literature and found supporting 
evidence of the tumor suppressing functions of 22 (78.6%) novel TSGs. Many of these 
novel TSGs were also annotated as putative drivers by other computational methods 








Figure 3.13. Positional distributions of somatic mutations in SOX9 in colon cancer. 
Evolutionary conservation of each position, measured as number of substitutions per 













Figure 3.14. Positional distributions of somatic mutations in BMPR2 in stomach 
adenocarcinomas. Evolutionary conservation of each position, measured as number of 
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3.4.3.3 Spectrum of Tissue Specificity 
Even after removing low-confidence predictions, most of the drivers annotated by 
GUST were engaged in only one cancer type, showing high tissue specificities. Only 13 
(59.1%) OGs and 25 (33.8%) TSGs in this high-confidence set are broad-spectrum 
drivers, promoting tumorigenesis in two or more cancer types (Fig. 3.16). The most 
prevalent OG was the PIK3CA gene found in 15 cancer types with high confidence, 
followed by the KRAS/NRAS/HRAS genes found in 13 cancer types. The most prevalent 
TSG was the TP53 gene found in 18 cancer types, followed by the ARID1A gene found 
in 10 cancer types. 
 
Figure 3.16. Distribution of driver genes with different spectrum of tissue specificity. 
 
Furthermore, 11 out of the 13 broad-spectrum OGs possessed multiple hotspots 
(one-sided proportional test P <0.05 after Bonferroni corrections, Supplementary Figure 
5, Supplementary Methods). For each significant hotspot, we examined the affected 
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functional domains as annotated in the NCBI Gene database. A representative example is 
the EGFR gene. In lung adenocarcinoma, 48% of missense mutations clustered at a single 
mutational hotspot affecting the tyrosine kinase activation loop (Fig. 3.17). In glioma, 
only one mutation hit this loop (chi-square test P < 10-18), and 69.3% of all missense 
mutations clustered at two hotspots affecting the extracellular domains independent of 
kinase activities. The contextual selection of mutations averting the kinase catalytic 
domain in glioma suggests an alternate path of activating EGFR signaling. In fact, several 
studies have reported the associations of these hotspot mutations with different levels of 
EGFR activities (Kamburov et al. 2015; Niu et al. 2016; Porta-Pardo et al. 2017).  
 
 
Figure 3.17. Positional distribution of mutations in the EGFR gene in lung 
adenocarcinoma and glioma (low-grade glioma and glioblastoma combined) 
 
 
Interestingly, each of the 33 cancer types engaged at least one broad-spectrum 
driver and multiple tissue-specific drivers, implicating the synchrony of convergent and 
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divergent disease pathways. Clustering of cancers based on broad-spectrum driver genes 










Figure 3.18. Two-way clustering of driver genes and cancer types. Driver genes found in 




Distinguishing OGs and TSGs in individual cancer types is critical to 
understanding cancer etiology and pinpointing clinically actionable targets. In this 
chapter, we proved that protein-coding mutations in OGs and TSGs are under different 
somatic selection, and subsequently discussed the GUST method to discover cancer-type 
specific functions of cancer driver genes. We compared GUST with the 20/20+ method, 
which is the only available method to classify OGs and TSGs. Both GUST and 20/20+ 
employ a random forest model to integrate features extracted from tumor exomes. 
Although GUST uses only 10 features compared to 24 features in 20/20+, the accuracy of 
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GUST is consistently higher. In the GUST model, selection measures contribute the most 
information content. In 20/20+, the p-value of enrichment of inactivating mutations is the 
most informative feature. Interestingly, this feature is also related to selection, although it 
is not a strict evolutionary measure (Kryazhimskiy and Plotkin 2008; Temko et al. 2018). 
These results suggest that using a small number of features engineered on evolutionary 
mechanisms is more powerful than feeding a large number of raw features to machine 
learning models. Furthermore, given the scarcity of known drivers for specific cancer 
types, reducing the number of features in predictive models helps mitigate overfitting 
problems.  
We acknowledge that a driverMAPS (Zhao et al. 2019) method has been recently 
developed that estimates selection coefficients of a gene under three competing models 
(i.e., a PG, an OG and a TSG model). However, this method later combines the OG 
model and the TSG model into a driver model and contrasts it with the PG model to 
predict driver genes. Consequently, the reported posterior likelihood and false discovery 
rate are for the purpose of distinguishing drivers and passenger, but not OGs versus 
TSGs. Via personal communications with the authors of driverMAPS, we confirmed that 
this method does not provide statistical significance of OG and TSG classifications. 
Therefore, we did not compare GUST with driverMAPS. 
While we discovered many known and novel cancer driver genes, none of them 
showed dual OG/TSG roles with high confidence in our analysis. A straightforward 
explanation is that GUST makes predictions based on protein altering substitutions and 
indels, thus it is unable to capture genes acting through other mechanisms, such as 
noncoding regulatory variants, copy number variants, translocations, fusions, differential 
  91 
expressions, post-translational modifications and epigenetic regulations. Further 
investigations will shed light on key switches that divert paths of dual-role drivers. We 
also note that genes with only a small number of mutations may cause non-convergence 
problems during maximum likelihood estimations of selection coefficients, which limits 
the application of GUST to discovering rare drivers. 
For practical use, we have built an online database 
(https://liliulab.shinyapps.io/gust) with precomputed results of analyzing TCGA samples. 
Users can query the database and visually inspect somatic selection patterns and 
conservational patterns of selected genes. Combined with information indicating whether 
or not a gene has been annotated by CGC as a driver or a drug target, users can make 
informed decisions on prioritizing candidate genes for further investigations. The R 
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CHAPTER 4 
SUBCLONAL DISTRIBUTIONS OF CANCER DRIVERS & PROGNOSTIC VALUES 
4.1 Introduction  
 In chapter 2, we discussed the clinical implication and importance of discovering 
clonal structure of the tumors. We developed MAGOS to discover this structure and 
applied it to data from 33 cancer types from TCGA. We found interesting associations 
between the number of subclones and the survival of patients, in LIHC and ACC and 
THYM. In chapter 3, we introduced GUST, a random forest method to predict cancer-
specific driver genes. We argued that genes’ roles in cancers are not universal and 
depends on the cancer type. GUST is able to predict each gene’s role, specific to each 
cancer type. We applied GUST to TCGA data, and detected the driver genes for each 
sample (OG, TSG, PG). We considered the cluster with the highest VAF as the major 
clone and the remaining clusters as sub-clones. 
 In this chapter, we are focusing on combining the results of chapter 2 and chapter 
3 by overlaying clonal information and the roles of the genes.  In doing so, we will 
investigate whether subclonal drivers are effective for patient survival. The results of this 
analysis will help us understand the progression of the disease, may point to potential 
candidates for targeted therapies, and help with early disease detections by discovering 
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4.2 Combining MAGOS and GUST 
 MAGOS works with mutations from a tumor sample from an individual patient, 
whereas GUST utilizes all of the mutations from a specific cancer type as input and 
predicts the class of each gene for that cancer. In order to overlay the results, the clonality 
information for each specific mutation comes from MAGOS, and the gene type comes 
from the GUST output. For each patient, we will have the counts of clonal OGs, clonal 
TSGs, subclonal OGs and subclonal TSGs. Using the clinical data for each patient we can 
study the survival time of the patients and the clonal/driver features.  
4.3 MAGOS + GUST Results  
This section highlights the results found by analyzing the association between the 
survival and the clonal distribution of the driver genes on the 33 cancer types from 
TCGA.  We discovered an association between the clonal distribution of the drivers and 
the survival of the patients, in ACC, READ, LIHC, OV and HNSC. Although, in the 
majority of the cancer types, we were not able to detect any significant association.  
4.3.1 Adenoid Cystic Carcinoma (ACC) 
Subclonal Tumor suppressor genes in Adenoid cystic carcinoma showed an 
association with increased survival of the patients. We saw that if a patient does not have 
any TSG mutations, they tend to survive longer (p-value= 0.05, Table 4.1, Fig. 4.1). 
However, most of this TSGs occurs in the subclone and there are only 4 samples that 
have TSG mutations in their clone (Fig 4.2). Patients with no TSG in their subclone tend 
to survive longer as well (p-value= 0.04, Fig 4.3).  
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Table 4.1. Clonal distribution of the driver genes detected in ACC. The gray cells 
correspond to the p-value of a test with: h0: having a Driver (All/OG/TSG) in 
Clone(Either/Clone/Subclone) is not associated with survival. The white cells correspond 









Figure 4.1. Kaplan Meier curve of the patients with no TSG in neither clone nor subclone 
vs patients with at least one TSG. 
 ALL Clonal Subclonal 
OG+TSG 0.02 1 0.02 
  30 vs 32  51 vs 11  40 vs 22 
OG 0.2 0.9 0.01 
  50 vs 12  54 vs 8  58 vs 4 
TSG 0.05 0.9 0.04 
  38 vs 24 58 vs 4 42 vs 20 
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Figure 4.2. Kaplan Meier curve of the patients with no TSG in their clone vs patients with 
at least one clonal TSG. 
 
 
Figure 4.3. Kaplan Meier curve of the patients with no TSG in subclone vs patients with 
at least one subclonal TSG. 
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4.3.2 Liver Hepatocellular Carcinoma (LIHC) 
 Results for LIHC have already been reported in the MAGOS section. In patients 
with stage III of LIHC, we found significant association between survival of the patient 
and the detected number of subclones. In adding the GUST analysis results, we also 
found an association between the survival of the patient and the number of 
clonal/subclonal drivers across all of the samples. This was also observed in the data 
from stage III LIHC.  
 Across all of the LIHC samples, we discovered that the existence of subclonal 
driver mutations is associated with the survival (p-value=0.05), whereas clonal drivers do 
not have the same effect on survival (p-value=0.6) (Table 4.2, Fig. 4.4, Fig. 4.5 and Fig. 
4.6).  Interestingly, not having a driver gene in either the clone or subclone will not 
increase the survival rate of patients.  
 
Table 4.2. Clonal distribution of the driver genes detected in LIHC. The gray cells 
correspond to the p-value of a test with: h0: having a Driver (All/OG/TSG) in Clone 
(Either/Clone/Subclone) is not associated with survival. The white cells correspond to the 




 ALL Clonal Subclonal 
OG+TSG 0.3 0.6 0.05 
  36 vs 324 135 vs 225 107 vs 253 
OG 0.6 0.3 0.06 
  235 vs 125 297 vs 63 289 vs 71 
TSG 0.3 0.5 0.2 
   52 vs 309 159 vs 202  122 vs 238 
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Figure 4.4. Kaplan Meier curve of the patients with no Driver vs patients with at least one 
Driver in either clone or subclone. 
 
 
Figure 4.5. Kaplan Meier curve of the patients with no driver in clone vs patients with at 
least one clonal driver. 
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Figure 4.6. Kaplan Meier curve of the patients with no subclonal driver vs patients with 
at least one subclonal driver. 
 
We used Cox proportional hazard regression to test if the number of clonal or 
subclonal drivers in a tumor is associated with patient overall survival. We included age 
at diagnosis, tumor stages and number of detected clusters as covariates. We found 
significant association between number of subclonal oncogenes and the survival (p-
value=0.039, HR=1.38). For comparison, age at diagnosis is not a significant prognostic 
factor among these tumors (p-value=0.31). Among all LIHC tumors, the number of 
subclonal oncogenes is a novel prognostic factor for liver cancers that is independent of 
age at diagnosis, and total number of clusters. 
We also analyzed Stage III LIHC and found interesting results. We discovered 
that in stage III liver cancer, subclonal OGs have the most significant prognosis power 
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(p-value=0.01). Existence of Subclonal OG are the most significant feature in predicting 
survival, even more than age at diagnosis (Table 4.3, Fig. 4.7, Fig. 4.8, Fig. 4.9).   
Table 4.3. Clonal distribution of the driver genes detected in LIHC Stage III. The gray 
cells correspond to the p-value of a test with: h0: having a Driver (All/OG/TSG) in Clone 
(Either/Clone/Subclone) is not associated with survival. The white cells correspond to the 
number of samples without any driver vs number of samples with the driver. 
 
 ALL Clonal Subclonal 
OG+TSG 0.3 0.9 0.2 
  7 vs 76 32 vs 51 22 vs 61 
OG 0.07 0.7 0.01 
  51 vs 32 65 vs 18 68 vs 15 
TSG 0.6 0.8 0.5 
  12 vs 71 41 vs 42 25 vs 58 
 
 
Figure 4.7. Kaplan Meier curve of the patients with no OG vs patients with at least one 
OG. 
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Figure 4.8. Kaplan Meier curve of the patients with no clonal OG vs patients with at least 
one clonal OG. 
 
 
Figure 4.9. Kaplan Meier curve of the patients with no subclonal OG vs patients with at 
least one subclonal OG. 
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Using Cox proportional hazard regression, we tested if the number of clonal or 
subclonal drivers in a tumor is associated with patient overall survival in stage III LIHC, 
We included age at diagnosis, and number of detected clusters as covariates. In analyzing 
all of the LIHC tumors across all tumor stages, number of clusters, do not have any 
associations. Number of subclonal oncogenes also is not associated with survival as 
opposed to all LIHC data.  
4.3.3 Head and Neck Squamous Cell Carcinoma (HNSC) 
 In head and neck squamous cell carcinoma, we detected associations between the 
lack of subclonal drivers and the survival of the patients. By looking closely, we 
discovered that this association is mainly from subclonal TSGs (p-value=0.03) rather than 
the OGs. Because subclonal OGs do not have association with survival (p-value=0.4, 
Table 4.4, Fig.4.10, Fig. 4.11, Fig.4.12, Fig.4.13). 
 
 
Table 4.4. Clonal distribution of the driver genes detected in HNSC. The gray cells 
correspond to the p-value of a test with: h0: having a Driver (All/OG/TSG) in Clone 
(Either/Clone/Subclone) is not associated with survival. The white cells correspond to the 
number of samples without any driver vs number of samples with the driver. 
 
 
ALL Clonal Subclonal 
OG+TSG 1 0.5 0.05 
  6 vs 488 88 vs 405 46 v 447 
OG 0.6 0.1 0.4 
  321 vs 173 435 vs 59 369 vs 125  
TSG 0.5 0.1 0.03 
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Figure 4.10. Kaplan Meier curve of the patients with no clonal driver vs patients with at 
least one clonal driver. 
 
 
Figure 4.11. Kaplan Meier curve of the patients with no subclonal driver vs patients with 
at least one subclonal driver. 
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Figure 4.12. Kaplan Meier curve of the patients with no clonal TSG vs patients with at 
least one clonal TSG. 
 
 
Figure 4.13. Kaplan Meier curve of the patients with no subclonal TSG vs patients with 
at least one subclonal TSG. 
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 Using Cox proportional hazard regression, we did not find any associations 
between the clonal/subclonal drivers and the survival of the patients.  
4.3.4 Low Grade Glioma (LGG) 
In Low Grade Glioma, OGs seem to have prognostic value. First, we discovered 
that having a clonal driver (p-value=0.0002, table 4.5) effects the rate of patient survival. 
Not having any drivers is significant in predicting survival. However, looking further at 
the clonal distribution of the drivers, the clonal drivers are more important than the 
subclonal drivers (table 4.5). In figures 4.14-4.19 we can see the effect of clonal drivers 
and the OG, specifically.   
 
Table 4.5. Clonal distribution of the driver genes detected in LGG. The gray cells 
correspond to the p-value of a test with: h0: having a Driver (All/OG/TSG) in Clone 
(Either/Clone/Subclone) is not associated with survival. The white cells correspond to the 
number of samples without any driver vs number of samples with the driver. 
 
 
ALL Clonal Subclonal 
OG+TSG 0.01 0.0002 0.1 
  14 vs 494 85 vs 423 147 vs 361 
OG 0.00001 0.00001 0.07 
  54 vs 454 178 vs 330 365 vs 143 
TSG 0.5 0.6 0.6 
   63 vs 447 206 vs 304   191 vs 319 
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Figure 4.14. Kaplan Meier curve of the patients with no clonal driver vs patients with at 
least one clonal driver. 
 
  
Figure 4.15. Kaplan Meier curve of the patients with no subclonal driver vs patients with 
at least one subclonal driver. 
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Figure 4.17. Kaplan Meier curve of the patients with no clonal OG vs patients with at 
least one clonal OG. 
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Figure 4.18. Kaplan Meier curve of the patients with no subclonal OG vs patients with at 
least one subclonal OG. 
 
 We did not have tumor stage data reported for the LGG patients. We used Cox 
proportional hazard regression to test if there is any association between the 
clonal/subclonal drives, number of clusters, and other covariates and the survival of the 
patients. We found that using age at diagnosis, clonal/subclonal drivers, and the number 
of clusters as covariates, age at diagnosis (p-value<0.0001, HR=1), number of clonal 
oncogenes (p-value<0.0001, HR=0.319) and number of subclonal oncogenes (p-
value<0.028, HR=0.59) have significant association with survival. Although, the 
association between the number of clonal and subclonal oncogenes and the survival is 
negative. In other words, the patients with more clonal/subclonal oncogenes live longer 
than the patients with fewer oncogenes.  
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4.3.5 Rectum Adenocarcinoma (READ) 
 In the rectum adenocarcinoma, we observed an association between the 
distribution of oncogenes and the survival rate of patients. We observed a strong 
association between subclonal drivers and survival, though, there were not many samples 
that did not have any subclonal drivers (table 4.6). Interestingly, the clonal distribution of 
OGs have a strong association with survival. In figures 4.19-4.21 we can see that the 
samples with subclonal OG have higher a survival chance vs patients with subclonal 
OGs. This example is one case that demonstrates the power of the results that can be 
obtained from analyzing the results of MAGOS and GUST. We can see that the existence 
of clonal OGs are not associated with survival whereas subclonal OG is strongly 
associated with the survival of the patient.  
 
Table 4.6. Clonal distribution of the driver genes detected in READ. The gray cells 
correspond to the p-value of a test with: h0: having a Driver (All/OG/TSG) in Clone 
(Either/Clone/Subclone) is not associated with survival. The white cells correspond to the 
number of samples without any driver vs number of samples with the driver. 
 
 ALL Clonal Subclonal 
OG+TSG 0.9 0.4 0.005 
  1 vs 132 26 vs 107 8 vs. 125 
OG 0.6 0.3 0.05 
  52 vs 81 90 v 43 87 vs 46  
TSG 0.9 1 0.003 
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Figure 4.20. Kaplan Meier curve of the patients with no clonal OG vs patients with at 
least one clonal OG. 
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Figure 4.21. Kaplan Meier curve of the patients with no subclonal OG vs patients with at 
least one subclonal OG. 
 
Using Cox proportional hazard regression, we tested if the number of clonal or 
subclonal drivers in a tumor is associated with patient overall survival in READ, We 
included age at diagnosis, and number of detected clusters and tumor stage as covariates. 
Number of subclonal tumor suppressor genes (p-value=0.032, HR=0.45) and age at 
diagnosis (p-value=0.03, HR=1) were found to be significantly associated with the 
survival. The number of subclonal tumor suppressor genes have a negative association 
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4.3.6 Ovarian Cancer (OV) 
 In Ovarian cancer samples, subclonal drivers have the most impact on survival. 
However, interestingly in OV, the association has a negative effect. This means that if the 
patient has subclonal driver, they tend to live longer than if they do not have subclonal 
drivers (table 4.7, Fig.4.22, Fig 4.23, and Fig.4.24).  
 
 
Table 4.7. Clonal distribution of the driver genes detected in OV. The gray cells 
correspond to the p-value of a test with: h0: having a Driver (All/OG/TSG) in Clone 
(Either/Clone/Subclone) is not associated with survival. The white cells correspond to the 
















 ALL Clonal Subclonal 
OG+TSG 0.5 0.3 0.03 
 6 vs 270 115 v 160 23 v 252 
OG 0.07 0.4 0.03 
 234 v 41 270 v 5 239 v 36 
TSG 0.4 0.3 0.02 
 7 v268 117 v 158 24 v 251 




Figure 4.22. Kaplan Meier curve of the patients with no clonal TSG vs patients with at 
least one clonal TSG. 
 
 
Figure 4.23. Kaplan Meier curve of the patients with no subclonal TSG vs patients with 
at least one subclonal TSG. 
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Figure 4.24. Kaplan Meier curve of the patients with no subclonal OG vs patients with at 
least one clonal OG. 
 
 We did not have tumor stage data reported for the OV patients. We used Cox 
proportional hazard regression to test if there is any association between the 
clonal/subclonal drives, number of clusters, and other covariates and the survival of the 
patients. We found that using age at diagnosis, clonal/subclonal drivers, and the number 
of clusters as covariates, age at diagnosis (p-value=0.0012, HR=1) and number of clusters 
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4.3.7 Pan Cancer Analysis  
 After looking at each cancer separately, we conducted a pan cancer analysis. We 
tested whether across all of the cancers, if there are any features with prognosis value.  
We performed Cox proportional regression. Including number of clonal and subclonal 
drivers, age at diagnosis, tumor stage, and number of clusters and the expected survival 
of each cancer type as covariates in the model. We found that age at diagnosis, number of 
clonal oncogenes, number of clonal tumor suppressor genes, number of detected clones, 
number of mutations and tumor stage are significantly associated with the survival of the 
patient (table 4.8).  
Table 4.8. Cox regression results.  
 Coefficient  exp(Coef) P-Value 
Age at Diagnosis <0.001 1 <0.001 
Number of Clonal 
OGs 
-0.107 0.898 0.025 
Number of Subclonal 
OGs 
0.024 1.024 0.502 
Number of Clonal 
TSGs 
-0.037 0.964 0.009 
Number of Subclonal 
TSGs 
-0.01 0.99 0.117 
Number of Clusters 0.084 1.088 0.004 
Number of Mutations <0.001 0.999 0.08 
Expected Survival -0.032 0.969 <0.001 
Number of Clonal 
Passengers 
0.003 1.003 <0.001 
Number of Subclonal 
Passengers 
0.001 1.001 0.14 
Tumor Stage II 0.594 1.811 <0.001 
Tumor Stage III 0.952 2.59 <0.001 
Tumor Stage IV 1.347 3.848 <0.001 
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 The number of oncogenes and tumor suppressor genes found to be significantly 
associated with survival, but interestingly this association is reversed. In other words, 
more oncogenes or tumor suppressor genes in the clone results in longer survival. But for 
number of clusters this association is direct; more subclones, result in shorter survival 
time.   
4.4 Discussion 
Previous sections in this chapter discussed the clinical implication and importance 
of discovering the clonal structure of the tumor and discussed how MAGOS can be used 
to discover this structure.  Using MAGOS, we grouped the mutations from 33 cancer 
types’ samples from TCGA. We found significant associations between the number of 
subclones and the survival of the patients in LIHC, ACC and THYM. Next, we used 
GUST to predict cancer-specific driver genes. We applied GUST to TCGA data, and 
classified each mutated gene in each sample (OG, TSG, and PG). We considered the 
cluster with the highest VAF as the major clone and the remaining clusters as sub-clones. 
In this chapter, we combined the results of MAGOS and GUST and discovered 
associations between the clonal distribution of drives and the survival of each patient. By 
overlaying clonal information and the roles of the genes, we were able to identify 
important features with prognosis power that were significant in predicting the survival of 
the patient. In the pan cancer analysis, we discovered that the clonal drivers show a 
protective effect on survival. The patients with more clonal oncogenes or tumor 
suppressor genes survive longer vs the patients with fewer clonal drivers. On the other 
hand the number of subclones detected by MAGOS, has a negative effect on the survival. 
The patients with more subclones have shorter life span.  
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CHAPTER 5 
CONCLUSION AND FUTURE WORK 
 In this study, we attempted to better understand the progression of cancer and 
tried to find meaningful information from the available data. The aim was to study 
intratumor heterogeniety in cancer because it would provide us with valuable insights on 
how we can design treatment approaches to control the progression of the disease. We 
developed MAGOS to help us deconvolute the observed frequency of mutations in 
sequenced tumor samples. By applying MAGOS to TCGA data, we found that the 
number of subclones that could be detected by MAGOS have significant prognosis power 
in some cancer types (LIHC stage III). 
 In the next phase, we used GUST to predict the role of each gene in each cancer. 
Using TCGA data, we detected the number of driver genes in each sample of each 
cancer. The results can help us make hypotheses about the ways that each cancer may 
behave and progress. The next level of analysis was to merge the results of both studies. 
We merged our findings from both studies in order to look at the clonal distribution of 
drivers across different cancer types. Interestingly, the results showed that the total 
number of drivers in a sample may not be associated with the survival of the patient, but 
the clonal distribution of that specific driver may have strong associations. Our study 
showed that, in regards to LIHC, the lack of drivers is not associated with survival, but 
the lack of subclonal drivers can extend the survival of the patient.  
 The results we found are promising, but there is room to improve. There are 
several possible areas for development. The next step would be to develop methods to 
construct the clonal phylogeny, which by itself can provide valuable insights. Other 
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possible directions for development may include other covariates to improve prognostic 
values of our approach, and studying the disease mechanisms that we observed in order 
to discover the reasons that some tumors have positive correlations between clone counts 
with patient survival.  
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We model each cluster as a Beta distribution. We show that the variance of a beta 
distribution is positively correlated to the mean VAF and negatively correlated to the mean 
sequencing depth. This is important in clustering mutations in low coverage. Because if 
the model does not consider the coverage, the model will over estimate the number of 
clusters. In here, we show why the variance is higher in low coverage and also why the 
clusters with bigger mean VAF have larger variance.  
The variance of the beta distribution is: 
αβ
(α+β)2(α+β+1)




To look at the effect of VAF on variance, we keep the depth constant. With constant depth, 
higher VAF means bigger α. Since e̅ = α + β is constant, therefore β gets smaller. Therefore 
αβ is bigger. This results in higher variance. Since the denominator of the variance is 
constant and the numerator which is αβ increases. It is concluded that with constant depth, 
with higher VAF, the variance of the subclone increases.  
To study the effects of depth of sequencing for a subclone at a fixed VAF, we expect that 
the variance gets smaller if the depth of the sequencing is increased. If the new reference 
and alternate reads are α′and β′  the increased depth is α′ + β′and we have α′ + β′ > α + β . 



























We showed that the first and second part of the variance are unchanged but since α′ + β′has 
increased, the variance decreases.     
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The GUST algorithm, discussed in chapter 3 of this work is in press and expected 
to be published shortly after my dissertation defense. GUST is an algorithm designed 
with collaboration between Drs. Li Liu, Carlo Maley, Sudhir Kumar, Pramod 
Chandrashekar and myself, Navid Ahmadinejad. I am the second author of this paper. I 
contributed by applying the GUST algorithm to the TCGA data and analyzing the results 
as discussed in the publication. Pramod Chandrashekar developed the online database. 
All co-authors have granted their permissions for this work to be included in my 
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